| Номер в рекоменд. | Номер в разделе | Ссылка |
| | | 1. Введение |
| 1. | 1.1 | Naghavi M, Wang H, Lozano R, et al. Global, regional, and national age- sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117–71. |
| 2. | 1.2 | Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016; 37(42): 3232- 3245. |
| 3. | 1.3 | Демографический ежегодник России. 2015: Стат. сб. Росстат. – M., 2015. 263 С . |
| 4. | 1.4 | Бойцов СА, Самородская ИВ, Старинская МА, Семенов ВЮ, Какорина ЕП. Анализ структуры и динамики показателей смертности от болезней системы кровообращения в России в 2006 и 2014 гг. Профилактическая медицина 2016; 19(2-2): 11-12 |
| 5. | 1.5 | Погосова НВ, Оганов РГ, Суворов СВ. Почему в Москве смертность от сердечно-сосудистых заболеваний ниже, чем в других регионах Российской Федерации? Кардиоваскулярная терапия и профилактика 2015; 14(2): 4–12. |
| 6. | 1.6 | Калинина АМ, Ипатов ПВ, Кушунина ДВ, Егоров ВА, Дроздова ЛЮ, Бойцов СА. Результаты выявления болезней системы кровообращения при диспансеризации взрослого населения: опыт первых 2 лет. Терапевтический архив 2016; 88(1): 46-52. |
| 7. | 1.7 | Бойцов СА, Деев АД, Шальнова СА. Смертность и факторы риска неинфекционных заболеваний в России: особенности, динамика, прогноз. Терапевтический архив 2017; 89(1): 5-13. |
| 8. | 1.8 | Бокерия ЛА, Гудкова РГ. Сердечно-сосудистая хирургия 2014. – М., 2015. 226 С. |
| 9. | 1.9 | Ощепкова ЕВ, Коносова ИД, Ефремова ЮЕ. О заседании профильной комиссии по кардиологии от 3 июня 2016 г. Кардиологический Вестник 2016; 3: 4-11. |
| 10. | 1.10 | Медико-демографические показатели Российской Федерации. 2014 год. Стат. справочник. Минздрав России. – М., 2015. 186 С. |
| 11. | 1.11 | Бойцов СА, Самородская ИВ. Динамика сердечно-сосудистой |
| | | смертности среди мужчин и женщин в субъектах Российской Федерации (2002-2011 гг). Кардиология 2014; 54(4): 4-9. |
| 12. | 1.12 | Погосова НВ, Оганов РГ, Бойцов СА, Аушева АК, Соколова ОЮ, Курсаков АА, Поздняков ЮМ, Салбиева АО, Лельчук ИН, Гусарова ТА, Гомыранова НВ, Сказин НА, Елисеева НА, Ахмедова ЭБ, Бедейникова КК, Ковригина МН. Мониторинг вторичной профилактики ишемической болезни в России и Европе: результаты российской части международного многоцентрового исследования EUROASPIRE IV. Кардиология 2015; 55 (12): 5-11. |
| 13. | 1.13 | Министерство здравоохранения и социального развития Российской Федерации, Департамент организации медицинской профилактики, медицинской помощи и развития здравоохранения, ФГБУ «Центральный научно-исследовательский институт организации и информатизации здравоохранения» Министерства здравоохранения и социального развития российской федерации. Медико- демографические показатели Российской Федерации 2010 год. Статистические материалы. Москва. 2011. |
| 14. | 1.14 | Рожкова ТИ. Клинико-эпидемиологический анализ качества оказания медицинской помощи больным с инсультом в отдельных регионах Российской Федерации (по данным госпитального регистра): Автореф. дис. канд. мед. наук. Ульяновск 2011: 24 . |
| 15. | 1.15 | Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, et al., editors. The Global Economic Burden of Non- communicable Diseases. Geneva: World Economic Forum 2011. |
| 16. | 1.16 | Статистический сборник “Социально-экономические показатели Российской Федерации, 2016”, Госкомстат России. http:// www.cbsd.gks.ru |
| 17. | 1.17 | Braunwald’s Heart Disease: a textbook of cardiovascular medicine. Vol.1, chapter 1,2. Peter Libby, Robert O. Bonow, Douglas L. Mann, Douglas P. Zipes, Eugene Braunwald, 8th ed. - Elsevier Inc., 2008. 624p. ISBN 978-1- 4160-4160-1. |
| 18. | 1.18 | Hughes BB, Kuhn R, Peterson CM, et al. Projections of global health outcomes from 2005 to 2060 using the International Futures integrated forecasting model. Bull WHO 2011; 89: 478-486. Doi:10.2471/BLT.10.083766. |
| 19. | 1.19 | Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in mortality from coronary heart disease in the United States between 1980 and 2000. N Engl J Med 2007; 356: 2388-98 doi: 10.1056/NEJMsa053935 pmid: 17554120. |
| 20. | 1.20 | Jousilahti P, Laatikainen T, Peltonen M, Borodulin K, Männistö S, Jula A, Salomaa V, Harald K, Puska P, Vartiainen E. Primary prevention and risk factor reduction in coronary heart disease mortality among working aged men and women in eastern Finland over 40 years: population based observational study. BMJ 2016; 352: i721. doi: 10.1136/bmj.i721. |
| 21. | 1.21 | Cancer Control: Knowledge into Action: WHO Guide for Effective Programmes: Module 2: Prevention. Geneva: World Health Organization; 2007. |
| 22. | 1.22 | A Dictionary of Epidemiology. 4thed. New York: Oxford University Press. |
| 23. | 1.23 | Оганов РГ, Масленникова ГЯ. Эпидемию сердечно-сосудистых заболеваний можно остановить усилением профилактики. Профилактическая медицина 2009; 12(6): 3-5. |
| 24. | 1.24 | Yusuf S, Hawken S, Ounpu S, et al., on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case- control study. Lancet 2004;364:937-952. |
| 25. | 1.25 | O’Donnell M, Xavier D, Liu L, Zhang H. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE Study): a case-control study Reference. Lancet 2010; 376:112-123. |
| 26. | 1.26 | Rose G. The strategy of preventive medicine/ Oxford: Oxford University Press 1992. |
| 27. | 1.27 | Global strategy for prevention and control of non-communicable diseases. WHO (Geneva) 2008. |
| 28. | 1.28 | Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19(10): 1434-503. |
| 29. | 1.29 | De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10(4): S1-S78. |
| 30. | 1.30 | Graham I, Atar D, Borch-Johnsen K, et al. European Atherosclerosis Society (EAS). European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 Suppl 2: S1-113. |
| 31. | 1.31 | Бойцов СА, Оганов РГ. От профилактической кардиологии к профилактике неинфекционных заболеваний. Российский кардиологический журнал 2014; 102(4): 6. |
| 32. | 1.32 | Бойцов СА, Баланова ЮА, Шальнова СА, Деев АД, Артамонова ГВ, Гатагонова ТМ, Дупляков ДВ, Ефанов АЮ, Жернакова ЮВ, Конради АО, Либис РА, Минаков АВ, Недогода СВ, Ощепкова ЕВ, Романчук СВ, Ротарь ОП, Трубачева ИА, Чазова ИЕ, Шляхто ЕВ, Карпов РС. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика 2014; 13(4): 4-14. |
| 33. | 1.33 | Муромцева ГА, Концевая АВ, Константинов ВВ, Артамонова ГВ, Гатагонова ТМ, Дупляков ДВ, Ефанов АЮ, Жернакова ЮВ, Ильин ВА, Конради АО, Либис РА, Минаков АВ, Недогода СВ, Ощепкова ЕВ, Романчук СА, Ротарь ОП, Трубачева ИА, Деев АД, Шальнова СА, Чазова ЕИ, Шляхто ЕВ, Бойцов СА. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012- 2013гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная |
| | | терапия и профилактика 2014; 13(6): 4–11. doi:10.15829/1728-8800- 2014-6-4-11. |
| 34. | 1.34 | GATS глобальный опрос взрослого населения о потреблении табака. Российская Федерация, 2009, страновой отчет. http://www.who.int/tobacco/surveillance/ru_tfi_gatsrussian_countryrep ort.pdf |
| 35. | 1.35 | Комплексное наблюдение условий жизни населения. Таблица 1.61 http://www.gks.ru/free_doc/new_site/food1/survey0/index.html |
| 36. | 1.36 | Метельская ВА, Шальнова СА, Деев АД, Перова НВ, Гомыранова НВ, Литинская ОА, Евстифеева СЕ, Артамонова ГВ, Гатагонова ТМ, Гринштейн ЮИ, Дупляков ДВ, Ефанов АЮ, Жернакова ЮВ, Ильин ВА, Либис РА, Минаков АВ, Невзорова ВА, Недогода СВ, Романчук СА, Ротарь ОП, Трубачева ИА, Шляхто ЕВ, Бойцов СА, Баланова ЮА, Муромцева ГА, Капустина АВ, Мамедов МН. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина 2016; 1 (19): 15–23. |
| 37. | 1.37 | Шальнова СА, Деев АД, Метельская ВА, Евстифеева СЕ, Ротарь ОП, Жернакова ЮВ, Бойцов СА, Баланова ЮА, Гомыранова НВ, Имаева АЭ, Капустина АВ, Концевая АВ, Литинская ОА, Мамедов МН, Муромцева ГА, Оганов РГ, Суворова ЕИ, Худяков М.Б. Информированность и особенности терапии статинами у лиц с различным сердечно- сосудистым риском: исследование ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика 2016; 4 (15): 29–37. |
| 38. | 1.38 | Дедов ИИ, Шестакова МВ, Галстян ГР. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет 2016; 19(2): 104-112. |
| 39. | 1.39 | Dumith SC, Hallal PC, Reis RS, Kohl HW. World¬wide prevalence of physical inactivity and its association with human development index in 76 countries. Prev Med 2011; 53(1–2): 24–8. |
| 40. | 1.40 | Оганов РГ, Концевая АВ, Калинина АМ и соавт. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации. Кардиоваскулярная терапия и профилактика 2011; 4: 4-9. |
| 41. | 1.41 | Крысанова ВС, Журавлева МВ, Дралова ОВ. и соавт. Проблема ожирения и избыточной массы тела в Российской Федерации и ее фармакоэкономическая оценка. Альманах клинической медицины 2015 Февраль; 1: 36–41. |
| 42. | 1.42 | From Burden to “Best Buys”: Reducing the Economic Impact of Non- Communicable Diseases in Low- and Middle-Income Countries, World economic forum, WHO 2011. |
| 43. | 1.43 | World Health Organization. Scaling up action against noncommunicable diseases: how much will it cost? Geneva: World Health Organization 2011. |
| 44. | 1.44 | Mason H, Shoaibi A, Ghandour R, et al. A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries. PLoS One 2014; 9: e84445 |
| 45. | 1.45 | Using price policies to promote healthier diets, WHO 2015. |
| 46. | 1.46 | Allen K, Pearson-Stuttard J, Hooton W, Diggle P, Capewell S, O’Flaherty M. |
| | | Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: cost effectiveness modelling study. BMJ 2015; 351: h4583. doi:10.1136/bmj.h4583. |
| 47. | 1.47 | Концевая АВ, Калинина АМ, Бойцов СА, Ипатов ПВ. Социально- экономическая эффективность диспансеризации 2013 года в Российской Федерации. Кардиоваскулярная терапия и профилактика 2014; 3: 4-10. |
| 48. | 1.48 | McConnachie A, Walker A, Robertson M, Marchbank L, Peacock J, Packard CJ, Cobbe SM, Ford I. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. Eur Heart J 2014; 35: 290– 298. |
| 49. | 1.49 | Mistry H, Morris S, Dyer M, Kotseva K, Wood D, Buxton M. Cost- effectiveness of a European preventive cardiology programme in primary care: a Markov modeling approach. BMJ Open 2012; 2: e001029. |
| 50. | 1.50 | De Smedt D, Kotseva K, De Bacquer D, Wood D, De Backer G, Dallongeville J, Seppo L, Pajak A, Reiner Z, Vanuzzo D, Georgiev B, Gotcheva N, Annemans L. Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. Eur Heart J 2012; 33: 2865–2872. |
| 51. | 1.51 | Carnethon M, Whitsel LP, Franklin BA, et al. Worksite Wellness Programs for Cardiovascular Disease Prevention. Circulation 2009; 120: 1725-1741. |
| 52. | 1.52 | Anderson DR, Serxner SA, Gold DB. Conceptual framework, critical questions, and practical challenges in conducting research on the financial impact of worksite health promotion. Am J Health Promot 2001; 15: 281– 288. |
| 53. | 1.53 | Aldana SG. Financial impact of health promotion programs: a comprehensive review of the literature. Am J Health Promot 2001; 15: 296–320. |
| 54. | 1.54 | Пырикова НВ, Осипова ИВ, Концевая АВ и соавт. Клинико- экономическая эффективность организационной модели первичной профилактики сердечно-сосудистых заболеваний у работников железнодорожного транспорта. Российский кардиологический журнал 2014; 6: 12-14. |
| | | 2. Стратегии профилактики |
| 55. | 2.1 | Стратегия профилактики и контроля неинфекционных заболеваний и травматизма в Российской Федерации, Москва 2008. |
| 56. | 2.2 | Rose G. The strategy of preventive medicine/ Oxford: Oxford University Press 1992. |
| 57. | 2.3 | Global strategy for prevention and control of non-communicable diseases. WHO (Geneva) 2008. |
| 58. | 2.4 | Оганов РГ, Масленникова ГЯ, Колтунов ИЕ, Калинина АМ. Необходимые условия для профилактики сердечно-сосудистых заболеваний в Российской Федерации. Кардиоваскулярная терапия и профилактика 2010; 6: 4-9. |
| 59. | 2.5 | Оганов РГ, Погосова ГВ. Современные стратегии профилактики и лечения сердечно-сосудистых заболеваний. Кардиология 2007; 12; 4- 9. |
| 60. | 2.6 | Проект Стратегии формирования здорового образа жизни населения, профилактики и контроля неинфекционных заболеваний на период до 2025 года. Дата публикации 26.06.2017г. https://www.gnicpm.ru/UserFiles/Strategy_draft_26062017.pdf |
| | | 3. Суммарный сердечно-сосудистый риск: оценка и основные приоритеты |
| 61. | 3.1 | Blood Pressure Lowering Treatment Trialists’ Collaboration, Sundstrom J, Arima H, Woodward M, Jackson R, Karmali K, Lloyd-Jones D, Baigent C, Emberson J, Rahimi K, MacMahon S, Patel A, Perkovic V, Turnbull F, Neal B. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014; 384: 591–598. |
| 62. | 3.2 | Chamnan P, Simmons RK, Khaw KT, Wareham NJ, Griffin SJ. Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. BMJ 2010; 340: c1693. |
| 63. | 3.3 | Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24(11): 987-1003 . |
| 64. | 3.4 | Aktas MK, Ozduran V, Pothier CE, Lang R, Lauer MS. Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. JAMA 2004; 292: 1462–1468. |
| 65. | 3.5 | Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C,Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635–701. |
| 66. | 3.6 | van Dis I, Geleijnse JM, Boer JM, Kromhout D, Boshuizen H, Grobbee DE, van der Schouw YT, Verschuren WM. Effect of including nonfatal events in cardiovascular risk estimation, illustrated with data from The Netherlands. Eur J Prev Cardiol 2014; 21: 377–383. |
| 67. | 3.7 | Cooney MT, Dudina A, De Bacquer D, Fitzgerald A, Conroy R, Sans S, Menotti A, De Backer G, Jousilahti P, Keil U, Thomsen T, Whincup P, Graham I. How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators. Eur J Cardiovasc Prev Rehabil 2009; 16: 304–314. |
| 68. | 3.8 | Cooney MT, Dudina A, De Bacquer D, Wilhelmsen L, Sans S, Menotti A, De Backer G, Jousilahti P, Keil U, Thomsen T, Whincup P, Graham IM. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis 2009; 206: 611–616. |
| 69. | 3.9 | Cooney MT, Vartiainen E, Laatikainen T, De Bacquer D, McGorrian C, Dudina A, Graham I. Cardiovascular risk age: concepts and practicalities. Heart 2012; 98: 941–946. |
| | | 4. Коррекция поведенческих факторов риска |
| 70. | 4.1 | Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract 2005; 55: 305–312. |
| 71. | 4.2 | Artinian NT, Fletcher GF, Mozaffarian D, Kris-Etherton P, Van Horn L, Lichtenstein AH, Kumanyika S, Kraus WE, Fleg JL, Redeker NS, Meininger JC, Banks J, Stuart-Shor EM, Fletcher BJ, Miller TD, Hughes S, Braun LT, Kopin LA, Berra K, Hayman LL, Ewing LJ, Ades PA, Durstine JL, Houston- Miller N, Burke LE. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation 2010; 122: 406–441. |
| 72. | 4.3 | Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P, Foody JM, Franklin B, Sanderson B, Southard D, American Heart Association Exercise CR. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2007; 115: 2675–2682. |
| 73. | 4.4 | Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, McGee H, Mendes M, Niebauer J, Zwisler AD, Schmid JP. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010; 17: 1-17. |
| 74. | 4.5 | Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-81. doi: 10.1093/eurheartj/ehw106. Epub 2016 May 23. |
| 75. | 4.6 | Auer R, Gaume J, Rodondi N, Cornuz J, Ghali WA. Efficacy of in-hospital multidimensional interventions of secondary prevention after acute coronary syndrome: a systematic review and meta-analysis. Circulation 2008; 117: 3109–3117. |
| 76. | 4.7 | Janssen V, De Gucht V, Dusseldorp E, Maes S. Lifestyle modification programmes for patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol 2013; 20: 620–640. |
| 77. | 4.8 | Hazelton G, Williams JW, Wakefield J, Perlman A, Kraus WE, Wolever RQ. Psychosocial benefits of cardiac rehabilitation among women compared with men. J Cardiopulm Rehab Prev 2014; 34: 21–28. |
| 78. | 4.9 | Burell G, Granlund B. Women’s hearts need special treatment. Int J Behav Med 2002; 9: 228–242. |
| | | 5. Курение |
| 79. | 5.1 | Бойцов СА, Самородская ИВ. Факторы, влияющие на смертность населения. Вестник Российской академии наук 2016; 86(12): 1089-97. |
| 80. | 5.2 | Баланова ЮА, Шальнова СА, Деев АД, Капустина АВ, Константинов ВВ, Бойцов СА. Распространенность курения в России. Что изменилось за 20 лет? Профилактическая медицина 2015; 18 (6): 47-52. |
| 81. | 5.3 | Погосова НВ, Оганов РГ, Бойцов СА, Аушева АК, Соколова ОЮ, Курсаков АА, Поздняков ЮМ, Гомыранова НВ, Карпова АВ, Алленов АМ. Эффективность первичной профилактики заболеваний, обусловленных атеросклерозом, у пациентов с высоким сердечно- сосудистым риском в России и других странах Европы. Сердце 2017 (в печати). |
| 82. | 5.4 | Самородская ИВ, Бойцов СА. Повторный инфаркт миокарда: оценка, риски, профилактика. Российский кардиологический журнал 2017; 6(146): 139-145. |
| 83. | 5.5 | Погосова ГВ, Колтунов ИЕ, Соколова ОЮ. Вторичная профилактика артериальной гипертонии и ишемической болезни сердца в реальной клинической практике Российской Федерации. Москва, «Викас- принт» 2009. |
| 84. | 5.6 | Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’observations on male British doctors. BMJ 2004; 328: 1519. |
| 85. | 5.7 | Kiiskinen U, Vartiainen E, Puska P, Aromaa A. Long-term cost and life- expectancy consequences of hypertension. J Hypertens 1998; 16: 1103– 1112. |
| 86. | 5.8 | Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998; 316: 1043–1047. |
| 87. | 5.9 | Федеральный Закон «О защите здоровья населения от последствий потребления табака» (Федеральный Закон от 23 февраля 2013 года № 15-ФЗ). |
| 88. | 5.10 | Maslennikova GY, Oganov RG, Boytsov SA, et al. Russia SimSmoke: The Long-term Effects of Tobacco Control Policies on Smoking Prevalence and Smoking-Attributable Deaths in Russia. Tob Control 2014; Tobacco Control 2014; 23: 484-490. doi:10.1136/tobaccocontrol - 2013-051011. |
| 89. | 5.11 | Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998; 97(6): 596-601. |
| 90. | 5.12 | He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease—a meta-analysis of epidemiologic studies.N Engl J Med 1999; 340: 920–926. |
| 91. | 5.13 | Pisinger C, Dossing M. A systematic review of health effects of electronic cigarettes. Prev Med 2014; 69: 248–260. |
| 92. | 5.14 | McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev 2014; 12: CD010216. |
| 93. | 5.15 | Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J,Walker N. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013; 382: 1629–1637. |
| 94. | 5.16 | Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med |
| | | 1995; 333: 1196–1203. |
| 95. | 5.17 | Etter JF, Bullen C. A longitudinal study of electronic cigarette users. Addict Behav 2014; 39: 491–494. |
| 96. | 5.18 | Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med 2016; 4: 116–128. |
| 97. | 5.19 | Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking and smoking cessation in relation to mortality in women. JAMA. 2008; 299: 2037-2047. |
| 98. | 5.20 | Law MR, Morris JK,Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ 1997; 315: 973–980. |
| 99. | 5.21 | Гамбарян МГ, Бойцов СА, Салагай ОО. Создание системы мониторинга и оценки эффективности реализации мероприятий, направленных на предотвращение воздействия окружающего табачного дыма и сокращение потребления табака. Профилактическая медицина 2016; 19(6): 4-11. |
| 100. | 5.22 | Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004; 1: CD003041. |
| 101. | 5.23 | Woolf KJ, Zabad MN, Post JM, McNitt S, Williams GC, Bisognano JD. Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes. Am J Cardiol 2012; 110: 968–970. |
| 102. | 5.24 | WHO Europe evidence based recommendations on the treatment of tobacco dependence. Tobacco control 2002; 11: 44-46. |
| 103. | 5.25 | Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013; 5: CD009329. |
| 104. | 5.26 | Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; 1: CD000031. |
| 105. | 5.27 | Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; 4: CD006103. |
| 106. | 5.28 | Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2014; 1: CD000031. |
| 107. | 5.29 | Taylor T LD, Bryant A, Keyse L, Joloza MT Smoking-related behaviour and attitudes, 2005. London: Office for National Statistics, 2006. |
| 108. | 5.30 | West R. Key performance indicators: findings from the Smoking Toolkit Study. http://www.smokinginengland.info. |
| 109. | 5.31 | Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003; 290(1): 86-97. |
| 110. | 5.32 | Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005; 26(17): 1765-1773. |
| 111. | 5.33 | Iestra JA, Kromhout D, van der Schouw YT, Grobbee DE, Boshuizen HC, van Staveren WA. Effect Size Estimates of Lifestyle and Dietary Changes on All- Cause Mortality in Coronary Artery Disease Patients: A Systematic Review. Circulation 2005; 112: 924-934. |
| 112. | 5.34 | Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121: 750–758. |
| 113. | 5.35 | Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119–1127. |
| 114. | 5.36 | Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Europ Heart J 2016; 37(29): 2315-2381. |
| 115. | 5.37 | Международная статистическая классификация болезней и проблем связанных со здоровьем. Десятый пересмотрю Том 1 (часть 1). Всемирная организация здравоохранения. Женева. 1992. 698С.. |
| 116. | 5.38 | Fagerstrom KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addictive Behaviors. 1978; 3(34): 235–241. |
| 117. | 5.39 | Eisenberg MJ, Filion KB, Yavin D, еt al. Pharmacotherapy for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179(2): 135-144. |
| 118. | 5.40 | Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000; 160(7): 939-944. |
| | | 6. Питание |
| 119. | 6.1 | European Heart Network. Diet, Physical Activity and Cardiovascular Disease Prevention in Europe. Brussels, Belguim: European Heart Network 2011. |
| 120. | 6.2 | Мартинчик А.Н., Маев И.В., Янушевич О.О. Общая нутрициология. Учебное пособие. М.: Медпресс-информ, 2005, 392с. |
| 121. | 6.3 | Тутельян ВА, Вялков АИ, Разумов АН и соавт. Научные основы здорового питания; 2010; М.; Издательский дом «Панорама»; 816с. ISBN 978-5-86472-224-4. |
| 122. | 6.4 | Тутельян ВА, Самсонов МА, Каганов БС, Шарафетдинов ХЗ. Картотека блюд диетического (лечебного и профилактического) питания оптимизированного состава 2008; М.; 448с. |
| 123. | 6.5 | Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL; Authors/Task Force Members; Additional Contributor. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37(39): 2999-3058. |
| 124. | 6.6 | Global plan of action for non-communicable disease prevention and management by 2013-2020 WHO Renewed and revised draft Version at |
| | | 15 march 2013. http://www.who.int/cardiovascular_diseases/15032013_updated_revised _draft_action_plan_russian.pdf. |
| 125. | 6.7 | Recommended Dietary Pattern to Achieve Adherence to the American Heart Association/American College of Cardiology (AHA/ACC). Guidelines Circulation 2016; 134:00–00. DOI: 10.1161/CIR.0000000000000462. |
| 126. | 6.8 | Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Europ Heart J 2016; 37(29): 2315-2381. |
| 127. | 6.9 | Кардиоваскулярная профилактика. Национальные рекомендации. Кардиоваскулярная терапия и профилактика 2011;10 (6). Приложение 2. |
| 128. | 6.10 | Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr 2010; 91: 535–546. |
| 129. | 6.11 | Astrup A., Dyerberg J, Elwood P, Hermansen K, Hu FB, Jakobsen MU, Kok FJ, Krauss RM, Lecerf JM, LeGrand P, Nestel P, Riserus U, Sanders T, Sinclair A, Stender S, Tholstrup T, Willett WC. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010? Am J Clin Nutr 2011; 93: 684–688. |
| 130. | 6.12 | Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol1 EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA) EFSA Journal 2010; 8(3):1461. |
| 131. | 6.13 | Livingstone KM, Celis-Morales C, Navas-Carretero S, et al. Effect of an Internet-based, personalized nutrition randomized trial on dietary changes associated with the Mediterranean diet: the Food 4 Me Study. Am J Clin Nutr 2016; 104 288-297. |
| 132. | 6.14 | Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010; 92:1189–1196. |
| 133. | 6.15 | Mozaffarian D, Stampfer M J. Removing industrial trans fat from foods: a simple policy that will save lives. BMJ 2010; 340:345. |
| 134. | 6.16 | Downs Shauna M, Thowa Anne Marie & Leedera Stephen R. The effectiveness of policies for reducing dietary trans fat: a systematic review of the evidence. Systematic reviews Bull World Health Organ 2013; 91: 262–269H doi:10.2471/BLT.12.111468. |
| 135. | 6.17 | He FJ and MacGregor G.A. Salt reduction lowers cardiovascular risk: meta- analysis of outcome trials. Lancet 2011; 378; 9789: 380–382. |
| 136. | 6.18 | Taylor RS, Ashton KE, Moxham T, Hooper L, and Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (cochrane review). Am J Hypertension |
| | | 2011; 24; 8: 843–853. |
| 137. | 6.19 | O`Donnell MJ, Menthe A, Smith A, Yusuf S. Salt Intake and cardiovascular disease: why are the data inconsistent? Eur Heart J 2013; 34:1034-1040. |
| 138. | 6.20 | Bibbins-Domingo K, Chertow GM, Coxson PG, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010; 362(7): 590-599. |
| 139. | 6.21 | Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007; 334: 885-892. |
| 140. | 6.22 | Berz JP, Singer MR, et al. Use of a DASH food group. Arch Pediatr Adolesc Med 2011; 165: 540-546. |
| 141. | 6.23 | Баланова ЮА, Концевая АВ, Шальнова СА. и соавт. от имени участников исследования ЭССЕ-РФ. Распространенность поведенческих факторов риска сердечно-сосудистых заболеваний в Российской популяции по результатам исследования ЭСС-РФ. Профилактическая медицина 2014;17;5:42-53. |
| 142. | 6.24 | Волков ВС, Поселюгина ОБ, Нилова СА. Артериальная гипертония и потребление поваренной соли в России. Болезни сердца и сосудов 2009; 4: 16—18. |
| 143. | 6.25 | Rippe JM, Angelopoulos TJ. Added sugars and risk factors for obesity, diabetes and heart disease. Intern J Obesity 2016; 40: 22-27 | doi:10.1038/ijo.2016.10 |
| 144. | 6.26 | The American Heart Association's Diet and Lifestyle Recommendations 2016 http://www.heart.org/HEARTORG/HealthyLiving/HealthyEating/Nutrition /Added-Sugars_UCM_305858_Article.jsp#.WHYPsOztmko. |
| 145. | 6.27 | The FDA Says THIS Should Be Your Sugar Limit. http://www.refinery29.com/2015/11/97444/fda-sugar-recommendation |
| 146. | 6.28 | Oyebode O, Gordon-Dseagu V, Crowe FL, Roddam A W, Key T J, Appleby P N, at al. Fruit and vegetable intake and mortality from ischemic heart disease: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart study. 1235-1243.First published online:18 January 2011. DOI: http://dx.doi.org/10.1093/eurheartj/ehq465 |
| 147. | 6.29 | Walker A. Fruit and vegetables consumption and all cause, cancer and CVD mortality: analysis of Health Survey for England date. J Epidemiol Comm Health 2014 J Epidemiol Community Health. 2014; 68 (9):856-62. |
| 148. | 6.30 | Приказ МЗ РФ от 19 августа № 614.Об утверждении Рекомендаций по рациональным нормам потребления пищевых продуктов отвечающих современным требованиям здорового питания. http://rulaws.ru/acts/Prikaz-Minzdrava-Rossii-ot-19.08.2016-N-614/. |
| 149. | 6.31 | AbuMweis SS, Jew S, Ames NP. B-glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials. Eur J Clin Nutr 2010; 64: 1472–1480. |
| 150. | 6.32 | Wolever TM, Tosh SM, Gibbs AL, Brand-Miller J, Duncan AM, Hart V, Lamarche B, Thomson BA, Duss R, Wood PJ. Physicochemical properties of oat beta-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial. Am J Clin Nutr 2010; 92:723–732. |
| 151. | 6.33 | Chowdhury R, Stevens S, Gorman D, Pan A, Warnakula S, Chowdhury S, Ward H, Johnson L, Crowe F, Hu FB, Franco OH. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. BMJ 2012; 345: e6698. |
| 152. | 6.34 | Потребление основных продуктов питания населением Российской Федерации. Росстат, 2016. Consumption of main food groups in Russian Federation. Rosstat 2016. |
| 153. | 6.35 | Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic reviewand meta-analysis. BMJ 2011; 342: d671. |
| 154. | 6.36 | Holmes MV, Dale CE, Zuccolo L, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ 2014; 349: g4164. |
| 155. | 6.37 | Song М, Fung TT, Hu FB, Willett WC, Longo VD, Chan AT, Giovannucci EL, et al. Association of Animal and Plant Protein Intake With All-Cause and Cause-Specific Mortality. JAMA Intern Med. Published online 2016. doi:10.1001/jamainternmed.2016; 4182. |
| 156. | 6.38 | Abete I, Romaguera D, Vieira AR, Lopez de Munain A, Norat T. Association between total, processed, red and white meat consumption and all-cause, CVD and IHD mortality: a meta-analysis of cohort studies. Br J Nutr 2014; 112(5): 762-775. |
| 157. | 6.39 | Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and CHD mortality:an updated meta-analysis of seventeen cohort studies. Public Health Nutr 2012; 15: 725–737. |
| 158. | 6.40 | Dominik D Alexander, Paula E Miller, Ashley J Vargas, Douglas L Weed, Sarah S Cohen. Meta-analysis of Egg Consumption and Risk of Coronary Heart Disease and Stroke Journal of the American College of Nutrition 2016; 10: 704-716. DOI: 10.1080/07315724.2016.1152928 |
| 159. | 6.41 | Djoussé L, Gaziano JM Egg consumption and risk of heart failure in the Physicians' Health Study. Circulation 2008; 117 (4): 512-516. |
| 160. | 6.42 | Khawaja O, Singh H , Luni F, Kabour A , Ali SS, et al. Egg Consumption and Incidence of Heart Failure: A Meta-Analysis of Prospective Cohort Studies. Frontiers in Nutrition 2017; 3(4)10: 1-5 doi: 10.3389/fnut.2017.00010. |
| 161. | 6.43 | Pimpin L, Wu JHY, Haskelberg H, Del Gobbo L, Mozaffarian D. Is Butter Back? A Systematic Review and Meta-Analysis of Butter Consumption and Risk of Cardiovascular Disease, Diabetes, and Total Mortality. PLOS ONE 2016, doi: 10.1371/journal.pone.0158118. |
| 162. | 6.44 | Luo C, Zhang Y, Ding Y, Shan Z, Chen S, Yu M, Hu FB, Liu L. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all- cause mortality: a systematic review and meta-analysis. Am J Clin Nutr 2014; 100: 256–269. |
| 163. | 6.45 | World Health Organization Guideline: Sugars Intake for Adults and Children. Geneva: World Health Organization 2015. |
| | | 7. Избыточная масса тела |
| 164. | 7.1 | Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A, Sarwar N, Kizer JR, Lawlor DA, Nordestgaard BG, Ridker P, Salomaa V, Stevens J, Woodward M, Sattar N, Collins R, Thompson SG, Whitlock G, Danesh J. Separate and |
| | | combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011; 377: 1085 –1095. |
| 165. | 7.2 | Oreopoulos A, Padwal R, Norris CM, Mullen JC, Pretorius V, Kalantar- Zadeh K. Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis. Obesity 2008; 16: 442–450. |
| 166. | 7.3 | Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010; 363: 2211– 2219. |
| 167. | 7.4 | Муромцева ГА, Концевая АВ, Константинов ВВ и соавт. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013гг. Результаты исследования ЭССЕ- РФ. Кардиоваскулярная терапия и профилактика 2014; 13 (6): 4-11. |
| 168. | 7.5 | Чазова ИЕ, Ощепкова ЕВ. Борьба с сердечно-сосудистыми заболеваниями: проблемы и пути их решения на современном этапе. Вестник Росздравнадзора 2015; 5: 7-10. |
| 169. | 7.6 | Баланова ЮА, Концевая АВ, Шальнова СА. и соавт. от имени участников исследования ЭССЕ-РФ. Распространенность поведенческих факторов риска сердечно-сосудистых заболеваний в Российской популяции по результатам исследования ЭССЕ-РФ. Профилактическая медицина 2014; 17; 5: 42-53. |
| 170. | 7.7 | Погосова НВ, Оганов РГ, Бойцов СА, Аушева АК, Соколова ОЮ, Курсаков АА, Поздняков ЮМ, Салбиева АО, Лельчук ИН, Гусарова ТА, Гомыранова НВ, Сказин НА, Елисеева НА, Ахмедова ЭБ, Бедейникова КК, Ковригина МН. Мониторинг вторичной профилактики ишемической болезни в России и Европе: результаты российской части международного многоцентрового исследования EUROASPIRE IV. Кардиология 2015; 55 (12): 99-107. |
| 171. | 7.8 | Погосова НВ, Оганов РГ, Бойцов СА, Аушева АК, Соколова ОЮ, Курсаков АА, Поздняков ЮМ, Гомыранова НВ, Карпова АВ, Алленов АМ. Эффективность первичной профилактики заболеваний, обусловленных атеросклерозом, у пациентов с высоким сердечно- сосудистым риском в России и других странах Европы. Сердце 2017 (в печати). |
| 172. | 7.9 | Jensen MD, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: а report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Journal of the American College of Cardiology 2014; 63, 2985-3023. |
| 173. | 7.10 | Obesity: preventing and managing the global epidemic: report of a WHO consultation. (WHO technical report series ; 894), 2000. |
| 174. | 7.11 | Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen |
| | | ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). European Heart Journal 2016; 37(29): 2315- 2381. https://doi.org/10.1093/eurheartj/ehw106 |
| 175. | 7.12 | Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H, et al. Obesity Management Task Force of the European Association for the Study of Obesity. Obes Facts. 2015;8(6):402-24. doi: 10.1159/000442721. |
| 176. | 7.13 | NICE 2014.Obesity: identification, assessment and management. Clinical guideline. |
| 177. | 7.14 | Шальнова СА, Деев АД, Карамнова НС. Гендерные особенности связи образовательного статуса и характеристик массы тела по данным обследования национальной представительной выборки. Кардиоваскулярная терапия и профилактика 2009; 8(7): 17-24. |
| 178. | 7.15 | Петухов АБ, Никитюк ДБ, Сергеев ВН. Медицинская антропология: анализ и перспективы развития в клинической практике. Медпрактика. М. Москва. 2015. |
| 179. | 7.16 | Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, Lopez-Jimenez F. Association of body weight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006; 368: 666–678. |
| 180. | 7.17 | Rotar OB, et al. Metabolically healthy obese and metabolically unhealthy non-obese phenotypes in a Russian population. Eur J Epidemiol, published online, December 2016. |
| 181. | 7.18 | Шальнова СА, Деев АД, Капустина АВ и соавт. Масса тела и ее вклад в смертность от сердечно-сосудистых заболеваний и всех причин среди российского населения. Кардиоваскулярная терапия и профилактика, 2014; 13(1): 44-48. |
| 182. | 7.19 | Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53:1925–1932. |
| 183. | 7.20 | Bucholz EM, Rathore SS, Reid KJ, et al. Body mass index and mortality in acute myocardial infarction patients. Am J Med 2012; 125: 796–803. |
| 184. | 7.21 | Angerås O, Albertsson P, Karason K, et al. Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J 2013; 34: 345–353. |
| 185. | 7.22 | Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta- analysis. Am Heart J 2008; 156: 13–22. |
| 186. | 7.23 | Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. JAMA 2012; 308: 581–590. |
| 187. | 7.24 | Doehner W, Erdmann E, Cairns R, et al. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive |
| | | study population. Int J Cardiol 2012; 162: 20–26. |
| 188. | 7.25 | Jackson CL, Yeh HC, Szklo M, et al. Body-mass index and all-cause mortality in US adults with and without diabetes. J Gen Intern Med 2014; 29: 25–33. |
| 189. | 7.26 | Eckel R (ed.) Obesity: Mechanisms and Clinical Management. Lippincott: Williams &Wilkins 2003. |
| 190. | 7.27 | Российская ассоциация эндокринологов. Клинические рекомендации. Дефицит витамина D: диагностика, лечение и профилактика. Москва, 2015. |
| 191. | 7.28 | Avenell A, Broom J, Brown T, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8: 3-4, 1-182 |
| 192. | 7.29 | Rucker D, Padwal R, Li S, et al. Long term pharmacotherapy for obesity and overweigh: updated meta-analysis. British Medical Journal 2007; 335: 1194-1199 |
| 193. | 7.30 | Клинические рекомендации по лечению морбидного ожирения у взрослых. Российская Ассоциация Эндокринологов. Москва, 2014. |
| 194. | 7.31 | Клинические рекомендации по бариатрической и метаболической хирургии. Российское общество хирургов. Общество баритрических хирургов. Москва, 2014. |
| 195. | 7.32 | Приказ Министерства здравоохранения Российской Федерации от 9 ноября 2012 г. № 752н "Об утверждении стандарта первичной медико-санитарной помощи при ожирении". |
| 196. | 7.33 | Prevalence, Pathophysiology, Health Consequences and Treatment Options of Obesity in the Elderly: A Guideline. Obes Facts 2012; 5: 460-483 |
| 197. | 7.34 | Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long- term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160-167. |
| 198. | 7.35 | Нормы физиологических потребностей в энергии и пищевых веществах для различных групп населения Российской Федерации. Методические рекомендации МР 2.3.1.2432. Москва. 2008. |
| | | 8. Физическая активность |
| 199. | 8.1 | Nocon M, Hiemann T, Müller-Riemenschneider F, Thalau F, Roll S, Willich SN. Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. J Cardiovasc Prevent Rehabil 2008; 15(3): 239–46 |
| 200. | 8.2 | Lollgen H, Bockenhoff A, Knapp G. Physical activity and all-cause mortality: an updated meta-analysis with different intensity categories. Int J Sports Med 2009; 30: 213–224. |
| 201. | 8.3 | Talbot LA, Morrell CH, Fleg JL, Metter EJ. Changes in leisure time physical activity and risk of all-cause mortality in men and women: the Baltimore Longitudinal Study of Aging. Prev Med 2007; 45: 169–176. |
| 202. | 8.4 | Garrett S, Elley CR, Rose SB, O’Dea D, Lawton BA, Dowell AC. Are physical activity interventions in primary care and the community cost-effective? A systematic review of the evidence. Br J Gen Pract 2011; 61: e125–e133. |
| 203. | 8.5 | Marijon E, Tafflet M, Celermajer DS, Dumas F, Perier MC, Mustafic H, Toussaint JF, Desnos M, Rieu M, Benameur N, Le Heuzey JY, Empana JP, Jouven X. Sports related sudden death in the general population. |
| | | Circulation 2011; 124: 672–681. |
| 204. | 8.6 | Vanhees L, Geladas N, Hansen D, Kouidi E, Niebauer J, Reiner Z, Cornelissen V, Adamopoulos S, Prescott E, Borjesson M, Bjarnason- Wehrens B, Bjornstad HH, Cohen-Solal A, Conraads V, Corrado D, De Sutter J, Doherty P, Doyle F, Dugmore D, Ellingsen O, Fagard R, Giada F, Gielen S, Hager A, Halle M, Heidbuchel H, Jegier A, Mazic S, McGee H, Mellwig KP, Mendes M, Mezzani A, Pattyn N, Pelliccia A, Piepoli M, Rauch B, Schmidt-Trucksass A, Takken T, Buuren F, Vanuzzo D. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol 2012; 19: 1005–1033. |
| 205. | 8.7 | Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR Jr, Tudor- Locke C, Greer JL, Vezina J, Whitt-Glover MC, Leon AS. 2011 Compendium of Physical Activities: a second update of codes and MET values. Med SciSports Exerc 2011; 43: 1575–1581. |
| 206. | 8.8 | Howley ET. Type of activity: resistance, aerobic and leisure versus occupationalphysical activity. Med Sci Sports Exerc 2001; 33(6):S364– S369; discussion S419–S420. |
| 207. | 8.9 | Sattelmair J, Pertman J, Ding EL, et al. Dose response between physical activity risk of coronary heart disease: a meta-analysis. Circulation 2011; 124: 789–795. |
| 208. | 8.10 | Moore SC, Patel AV, Matthews CE, Berrington de Gonzalez A, Park Y, Katki HA, Linet MS, Weiderpass E, Visvanathan K, Helzlsouer KJ, Thun M, Gapstur SM, Hartge P, Lee IM. Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med 2012; 9: e1001335. |
| 209. | 8.11 | Schwingshackl L, Missbach B, Dias S, Konig J, Hoffmann G. Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a systematic review and network meta- analysis. Diabetologia 2014; 57: 1789–1797. |
| 210. | 8.12 | Physical Activity Guidelines Advisory Committee. Physical Activity Guidelines Advisory Committee Report, 2008. Washington, DC: U.S. Department of Health and Human Services 2008. |
| 211. | 8.13 | Стратегия в области физической активности для Европейского региона ВОЗ на 2016–2025 гг. |
| 212. | 8.14 | Глобальные рекомендации по физической активности для здоровья. Женева: Всемирная организация здравоохранения 2010 http://whqlibdoc.who.int/publications/2010/9789244599976_rus.pdf |
| 213. | 8.15 | Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). European Heart Journal 2016; 37(29): 2315- |
| | | 2381. https://doi.org/10.1093/eurheartj/ehw106 |
| 214. | 8.16 | Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, Swain DP. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011; 43: 1334–1359. |
| 215. | 8.17 | Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, Coke LA, Fleg JL,Forman DE, Gerber TC, Gulati M, Madan K, Rhodes J, Thompson PD, Williams MA. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation 2013;128:873–934. |
| 216. | 8.18 | Donnelly JE, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK. American College of Sports Medicine position stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2009; 41: 459–471. |
| | | 9. Артериальная гипертония |
| 217. | 9.1 | Constantino MI, Molyneaux L, Limacher-Gisler F, Al-Saeed A, Luo C, Wu T, Twigg SM, Yue DK, Wong J. Long-term complications and mortality in young onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care 2013; 36: 3863–3869. |
| 218. | 9.2 | Оганов РГ. Значение эпидемиологических исследований и доказательной медицины для клинической практики. Кардиоваскулярная терапия и профилактика 2015; 14(4) : 4-7. |
| 219. | 9.3 | Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A, Hosgood HD 3rd, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khatibzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcenes W, March L, Marks R, Martin R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman TR, Micha R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, Orchard J, Osborne R, Ostro B, Page A, Pandey KD, Parry CD, Passmore E, Patra J, Pearce N, Pelizzari PM, Petzold M, Phillips MR, Pope D, Pope CA 3rd, Powles J, Rao M, Razavi H, Rehfuess EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, Rodriguez-Portales JA, Romieu I, Room R, |
| | | Rosenfeld LC, Roy A, Rushton L, Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sapkota A, Seedat S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, Stapelberg NJ, Steenland K, Stockl H, Stovner LJ, Straif K, Straney L, Thurston GD, Tran JH, Van Dingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf AD, Yip P, Zielinski JM, Lopez AD, Murray CJ, Ezzati M, AlMazroa MA, Memish ZA. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224–2260. |
| 220. | 9.4 | Шальнова СА, Деев АД, Баланова ЮА, Капустина АВ, Имаева АЭ, Муромцева ГА, Киселева НВ, Бойцов СА. Двадцатилетние тренды ожирения и артериальной гипертонии и их ассоциации в России. Кардиоваскулярная терапия и профилактика 2017; 16(4): 4-10. DOI:10.15829/1728-8800-2017-4-4-10. |
| 221. | 9.5 | Бойцов СА, Баланова ЮА, Шальнова СА, Деев АД, Артамонова ГВ, Гатагонова ТМ, Дупляков ДВ, Ефанов АЮ, Жернакова ЮВ, Конради АО, Либис РА, Минаков АВ, Недогода СВ, Ощепкова ЕВ, Романчук СВ, Ротарь ОП, Трубачева ИА, Чазова ИЕ, Шляхто ЕВ, Карпов РС и соавт. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика 2014; 13(4): 4-14. |
| 222. | 9.6 | Шальнова СА, Деев АД, Баланова ЮА, Жернакова ЮВ, Конради АО, Бойцов СА от имени участников исследования «ЭССЕ-РФ». Лечение гипертонии у пациентов высокого риска. Монотерапия или комбинация? Лечащий врач 2016; 7: 17 –23. |
| 223. | 9.7 | Lawes CM, Van der Hoom C, Rodgers A. International Society of Hypertension: Global burden of blood-pressure-related disease. Lancet 2008; 371: 1513. |
| 224. | 9.8 | Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии 2010; 03: 5-26. |
| 225. | 9.9 | Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, Kario K, Lurbe E, Manolis A, Mengden T, O’Brien E, Ohkubo T, Padfield P, Palatini P, Pickering T, Redon J, Revera M, Ruilope LM, Shennan A, Staessen JA, Tisler A, Waeber B, Zanchetti A, Mancia G. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008; 26: 1505 –1526. |
| 226. | 9.10 | Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006;47:846 –853. |
| 227. | 9.11 | Viera А., Hinderliter А. Evaluation and Management of the Patient with Difficult-to-Control or Resistant Hypertension. Am Fam Physician 2009 ;79(10):863-869. |
| 228. | 9.12 | Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the |
| | | management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219. |
| 229. | 9.13 | SPRINT Research Group. A randomized trial of intensive versus standard bloodpressure control. N Engl J Med 2015; 373: 2103 –2116. |
| 230. | 9.14 | Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2017; DOI:10.1161/HYP.0000000000000066 |
| 231. | 9.15 | Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER, Simons-Morton DG, Karanja N, Lin PH. Effects on blood pressure of reduced dietary sodium the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344: 3–10. |
| 232. | 9.16 | Lochner J, Rugge B, Judkins D, Saseen J. Clinical inquiries. How effective are lifestyle changes for controlling hypertension? J Fam Pract 2006; 55(1):74. |
| 233. | 9.17 | Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). European Heart Journal 2016; 37(29): 315-2381. |
| 234. | 9.18 | Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Circulation 2008; 117(25): e510-26. |
| | | 10. Липиды плазмы крови |
| 235. | 10.1 | Cholesterol Treatment Trialists’ Collaboration, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581–590. |
| 236. | 10.2 | Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009; 53: 316–322. |
| 237. | 10.3 | Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, |
| | | Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjaerg-Hansen A. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population:guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478–3490a. |
| 238. | 10.4 | Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM. Ezetimibe added to statin therapy after acute coronary syndromes. NEngl J Med 2015; 372: 2387–2397. |
| 239. | 10.5 | Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 1490–1500. |
| 240. | 10.6 | European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S,Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–1818. |
| 241. | 10.7 | Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A,Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993–2000. |
| 242. | 10.8 | Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450–458. |
| 243. | 10.9 | Nordestgraard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points – a joint consensus statement drom the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory medicine. Eur Heart J 2016; 37(25): 1944-58. |
| 244. | 10.10 | Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF. Triglyceride-rich lipoproteins and high- density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345–1361. |
| 245. | 10.11 | Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–952. |
| 246. | 10.12 | Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006; 259: 481–492. |
| 247. | 10.13 | Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502. |
| 248. | 10.14 | Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KMA, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM, Ridker PM, Kastelein JJP. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins. JAMA 2012; 307: 1302–1309. |
| 249. | 10.15 | Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL, Authors/Task Force Members; 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. EurHeart J 2016; 37(39): 2999-3058. |
| 250. | 10.16 | Cholesterol Treatment Trialists’ Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681. |
| 251. | 10.17 | Preis SR, Hwang SJ, Coady S, Pencina MJ, D’Agostino RB Sr, Savage PJ, Levy D, Fox CS. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009; 119: 1728–1735. |
| 252. | 10.18 | Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007; 18: 1246–1261. |
| 253. | 10.19 | Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010; 160: p785–794.e10. |
| 254. | 10.20 | Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395–1407. |
| 255. | 10.21 | Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014; 5: CD007784. |
| 256. | 10.22 | Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 |
| | | diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo controlled trial. Lancet 2004; 364: 685– 696. |
| 257. | 10.23 | Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003; 361: 2005– 2016. |
| 258. | 10.24 | Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556–1565. |
| 259. | 10.25 | Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, LaRosa JC, DeMicco DA, Colhoun HM, Goldenberg I, Murphy MJ, MacDonald TM, Pedersen TR, Keech AC, Ridker PM, Kjekshus J, Sattar N, McMurray JJ. Lipid modifying therapies and risk of pancreatitis: a meta-analysis. JAMA 2012; 308: 804–811. |
| 260. | 10.26 | Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46: 1855–1862. |
| 261. | 10.27 | Марцевич СЮ, Кутишенко НП, Дроздова ЛЮ, Лерман ОВ, Невзорова ВА, Резник ИИ, Шавкута ГВ, Яхонтов ДА. Исследование РАКУРС: повышение эффективности и безопасности терапии статинами у больных с заболеваниями печени, желчного пузыря и/или желчевыводящих путей с помощью урсодеоксихолевой кислоты. Терапевтический архив 2014; 86(12): 48-52. |
| 262. | 10.28 | Диспансерное наблюдение больных хроническими неинфекционными заболеваниями и пациентов с высоким риском их развития. Методические рекомендации. Под ред. Бойцова СА и Чучалина АГ. М.: 2014.112 с. |
| 263. | 10.29 | Reiner Z, Galic M, Hanzevacki M, Tedeschi-Reiner E. Concomitant use of statins and cytochrome P 450 inhibitors in Croatia. Lijecnickivjesnik 2005; 127: 65–68. |
| 264. | 10.30 | Cholesterol Treatment Trialists’ Collaboration, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012; 7:e29849. |
| 265. | 10.31 | Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, Kastelein JJ, Colhoun H, Barter P. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011; 57: 1535–1545. |
| 266. | 10.32 | Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly-Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med 2012; 172: 144–152. |
| 267. | 10.33 | Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai |
| | | SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735–742. |
| 268. | 10.34 | Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, Sofat R, Stender S, Johnson PC, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MC, Tzoulaki I, Buxbaum SG, van der AD, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Veglia F, Ford I, Jukema JW, Westendorp RG, de Borst GJ, de Jong PA, Algra A, Spiering W, Maitland-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D, DIAGRAM Consortium, MAGIC Consortium, InterAct Consortium, Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJ, Lewsey JD, Chasman DI, Ridker PM, Maggioni AP, Tavazzi L, Ray KK, Seshasai SR, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, van der Harst P, Brunner EJ, Tybjaerg-Hansen A, Marmot MG, Krauss RM, Tsai M, Coresh J, Hoogeveen RC, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimaki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar N. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015; 385: 351–361. |
| 269. | 10.35 | Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008; 102(10 Suppl): 1K–34K. |
| 270. | 10.36 | Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489–1499. |
| 271. | 10.37 | Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500–1509. |
| 272. | 10.38 | Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, Plowchalk D, Sweeney K, Kaila N, Vincent J, Bays H. Results of bococizumab, a |
| | | monoclonal antibody against proproteinconvertasesubtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin- treated subjects with hypercholesterolemia. Am J Cardiol 2015; 115: 1212–1221. |
| 273. | 10.39 | AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255–2267. |
| 274. | 10.40 | Муромцева ГА, Концевая АВ, Константинов ВВ и соавт. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ- РФ. Кардиоваскулярная терапия и профилактика, 2014; 13(6): 4-11 |
| 275. | 10.41 | Метельская ВА. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ) Метельская ВА, Шальнова СА, Деев АД, Перова НВ, Гомыранова НВ, Литинская ОА, Евстифеева СЕ, Артамонова ГВ, Гатагонова ТМ, Гринштейн ЮИ, Дупляков ДВ, Ефанов АЮ, Жернакова ЮВ, Ильин ВА, Либис РА, Минаков АВ, Невзорова ВА, Недогода СВ, Романчук СА, Ротарь ОП, Трубачева ИА, Шляхто ЕВ, Бойцов СА, Баланова ЮА, Муромцева ГА, Капустина АВ, Мамедов МН. Профилактическая медицина 2016; 1 (19):15–23. |
| 276. | 10.42 | Результаты второго этапа мониторинга эпидемиологической ситуации по артериальной гипертонии в Российской Федерации (2005-2007 гг.), проведенного в рамках Федеральной целевой программы «Профилактика и лечение артериальной гипертонии в Российской Федерации». Информационно-статистический сборник. Москва 2008. |
| 277. | 10.43 | Погосова НВ, Оганов РГ, Бойцов СА, Аушева АК, Соколова ОЮ, Курсаков АА, Поздняков ЮМ, Гомыранова НВ, Карпова АВ, Алленов АМ. Эффективность первичной профилактики заболеваний, обусловленных атеросклерозом, у пациентов с высоким сердечно- сосудистым риском в России и других странах Европы. Сердце 2017 (в печати). |
| 278. | 10.44 | Погосова НВ, Оганов РГ, Бойцов СА, Аушева АК, Соколова ОЮ, Курсаков АА, Поздняков ЮМ, Салбиева АО, Лельчук ИН, Гусарова ТА, Гомыранова НВ, Сказин НА, Елисеева НА, Ахмедова ЭБ, Бедейникова КК, Ковригина МН. Мониторинг вторичной профилактики ишемической болезни в России и Европе: результаты российской части международного многоцентрового исследования EUROASPIRE IV. Кардиология 2015; 55 (12): 99-107. |
| | | 11. Сахарный диабет |
| 279. | 11.1 | Дедов ИИ, Шестакова МВ, Галстян ГР. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет 2016; 19 (2): 104-112. doi: 10.14341/DM2004116-17. |
| 280. | 11.2 | Ôunpuu S, Negassa A, Yusuf S. INTER-HEART: A global study of risk factors for acute myocardial infarction. Am Heart J 2001; 141: 711-21. |
| 281. | 11.3 | Constantino MI, Molyneaux L, Limacher-Gisler F, Al-Saeed A, Luo C, Wu T, Twigg SM, Yue DK, Wong J. Long-term complications and mortality in |
| | | young onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care 2013; 36:3863–3869. |
| 282. | 11.4 | Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, O’Keeffe LM, Gao P, Wood AM, Burgess S, Freitag DF, Pennells L, Peters SA, Hart CL, Haheim LL, Gillum RF,Nordestgaard BG, Psaty BM, Yeap BB, Knuiman MW, Nietert PJ, Kauhanen J, Salonen JT, Kuller LH, Simons LA, van der Schouw YT, Barrett- Connor E,Selmer R, Crespo CJ, Rodriguez B, Verschuren WM, Salomaa V, Svardsudd K, van der Harst P, Bjorkelund C, Wilhelmsen L, Wallace RB, Brenner H,Amouyel P, Barr EL, Iso H, Onat A, Trevisan M, D’Agostino RB Sr, Cooper C, Kavousi M, Welin L, Roussel R, Hu FB, Sato S, Davidson KW, Howard BV, Leening MJ, Rosengren A, Dorr M, Deeg DJ, Kiechl S, Stehouwer CD, Nissinen A, Giampaoli S, Donfrancesco C, Kromhout D, Price JF, Peters A, Meade TW, Casiglia E, Lawlor DA, Gallacher J, Nagel D, Franco OH, Assmann G, Dagenais GR, Jukema JW, Sundstrom J, Woodward M, Brunner EJ, Khaw KT, Wareham NJ, Whitsel EA, Njolstad I, Hedblad B,Wassertheil-Smoller S, Engstrom G, Rosamond WD, Selvin E, Sattar N, Thompson SG, Danesh J. Association of cardiometabolic multimorbidity with mortality. JAMA 2015; 314:52–60. |
| 283. | 11.5 | Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care 1990;13(4): 427-33. |
| 284. | 11.6 | UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–53. |
| 285. | 11.7 | ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi FN. Effects of intensive blood-pressure control in type 2 diabetes mellitus. New Engl J Med 2010; 362(17): 1575-85. |
| 286. | 11.8 | Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32(1): 187-192. doi: 10.2337/dc08-9026. |
| 287. | 11.9 | Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. The ADVANCE Collaborative Group, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572. |
| 288. | 11.10 | Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, Komajda M, McMurray JJ, RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373(9681): 2125-35. |
| 289. | 11.11 | Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, et al. Effect of sitagliptin on cardiovascular |
| | | outcomes in type 2 diabetes. N Eng J Med 2015; 373(3): 232–42. |
| 290. | 11.12 | Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Eng J Med 2013; 369(14): 1317–26. |
| 291. | 11.13 | Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, Lawson FC, Ping L, Wei X, Lewis EF, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Eng J Med 2015; 373(23): 2247– 57. |
| 292. | 11.14 | Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Eng J Med 2016; 375(4) :311–22. |
| 293. | 11.15 | Marso SP, Bain SC, Consoli A, et al., SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Eng J Med 2016; 375(19): 1834-1844. |
| 294. | 11.16 | Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией Дедова ИИ, Шестаковой МВ, Майорова АЮ. Сахарный диабет 2017; 20(1): 1-112. |
| 295. | 11.17 | Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117-2128. |
| 296. | 11.18 | James MT, Grams ME, Woodward M, Elley CR, Green JA, Wheeler DC, Paul de Jong, Gansevoort RT, Levey AS, Warnock DG, Sarnak MJ, On behalf of the CKD Prognosis Consortium. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with AKI. AM J Kidney 2015; 66(4): 602-612. |
| 297. | 11.19 | Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood Pressure Lowering in Type 2 Diabetes. A Systematic Review and Meta- analysis. JAMA 2015; 313(6): 603-615. doi:10.1001/jama.2014.18574 |
| 298. | 11.20 | Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta- analysis. Lancet 2016; 387: 957–67. |
| 299. | 11.21 | De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009; 339: b4531. |
| 300. | 11.22 | Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106. |
| | | 12. Психосоциальные факторы |
| 301. | 12.1 | Marmot M. Social determinants of health inequalities. Lancet 2005; 365: 1099–1104. |
| 302. | 12.2 | Mackenbach JP, Stirbu I, Roskam AJ, et al. Socioeconomic inequalities in health in 22 European countries. N Engl J Med 2008; 358: 2468–2481. |
| 303. | 12.3 | Gerber Y, Goldbourt U, Drory Y. Interaction between income and |
| | | education in predicting long-term survival acute myocardial infarction. Eur J Cardiovasc Prev Rehabil 2008; 15: 526–532. |
| 304. | 12.4 | Albert MA, Glynn RJ, Buring J, Ridker PM. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events. Circulation 2006;114: 2619–2626. |
| 305. | 12.5 | Alter DA, Franklin B, Ko DT, Austin PC, Lee DS, Oh PI, Stukel TA, Tu JV. Socioeconomicstatus, functional recovery, and long-term mortality among patients surviving acute myocardial infarction. PLoS One 2014; 8: e65130. |
| 306. | 12.6 | Barth J, Schneider S, von KaЁnel R. Lack of social support in the etiology and the prognosis of coronary heart disease: A systematic review and meta-analysis. Psychosom Med 2010; 72: 229–238 |
| 307. | 12.7 | Frasure-Smith N, Lespeґrance F, Gravel G, et al. Social support, depression, and mortality during the first year after myocardial infarction. Circulation 2000; 101: 1919–1924 |
| 308. | 12.8 | Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. J Am Coll Cardiol 2009; 53: 936–946. |
| 309. | 12.9 | Sogaro E, Schinina F, Burgisser C, et al. Type D personality impairs quality of life, coping and short-term psychological outcome in patients attending an outpatient intensive program of cardiac rehabilitation. Monaldi Arch Chest Dis 2010; 74: 181–191. |
| 310. | 12.10 | Denollet J. DS14: Standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med 2005; 67: 89–97. |
| 311. | 12.11 | Grande G, Romppel M, Barth J. Association between type D personality and prognosisin patients with cardiovascular diseases: a systematic review andmeta-analysis. Ann Behav Med 2012; 43: 299–310. |
| 312. | 12.12 | Denollet J, Schiffer AA and Spek V. A general propensity to psychological distress affects cardiovascular outcomes. CircCardiovascQual Outcomes 2010; 3: 546–557. |
| 313. | 12.13 | O’Dell KR, Masters KS, Spielmans GI, et al. Does type-D personality predict outcomes among patients with cardiovascular disease? A meta-analytic review. J Psychosom Res 2011; 71: 199–206. |
| 314. | 12.14 | Li J, Hansen D, Mortensen PB, et al. Myocardial infarction in parents who lost a child. A Nationwide prospective cohort study in Denmark. Circulation 2002; 106: 1634–1639. |
| 315. | 12.15 | Leor J, Poole WK and Kloner RA. Sudden cardiac death triggered by an earthquake. N Engl J Med 1996; 334: 413–419. |
| 316. | 12.16 | Meisel SR, Kutz I, Dayan KI, Pauzner H, Chetboun I, Arbel Y, David D. Effect of Iraqi missile war on incidence of acute myocardial infarction and sudden death in Israeli civilians. Lancet 199; 338(8768): 660-1. |
| 317. | 12.17 | Carroll D, Ebrahim S, Tilling K, et al. Admissions for myocardial infarction and World Cup football: Database survey. BMJ 2002; 325: 1439–1442. |
| 318. | 12.18 | Berntson J, Patel JS, Stewart JC. Number of recent stressful life events and incident cardiovascular disease: Moderation by lifetime depressive disorder. J Psychosom Res 2017; 99: 149-154. doi: 10.1016/j.jpsychores.2017.06.008. Epub 2017 Jun 12. |
| 319. | 12.19 | Оганов РГ, Погосова ГВ, Колтунов И.Е. и соавт. Депрессивная симптоматика ухудшает прогноз сердечно-сосудистых заболеваний и |
| | | снижает продолжительность жизни больных артериальной гипертонией и ишемической болезнью сердца. Кардиология 2011; 2: 59-66. |
| 320. | 12.20 | Kivimaki M, Jokela M, Nyberg ST, Singh-Manoux A, Fransson EI, Alfredsson L, Bjorner JB, Borritz M, Burr H, Casini A, Clays E, De Bacquer D, Dragano N, Erbel R, Geuskens GA, Hamer M, Hooftman WE, Houtman IL, Jockel KH, Kittel F, Knutsson A, Koskenvuo M, Lunau T, Madsen IE, Nielsen ML, Nordin M, Oksanen T, Pejtersen JH, Pentti J, Rugulies R, Salo P, Shipley MJ, Siegrist J, Steptoe A, Suominen SB, Theorell T, Vahtera J, Westerholm PJ, Westerlund H, O’Reilly D, Kumari M, Batty GD, Ferrie JE, Virtanen M. Long working hours and risk of coronary heart disease and stroke: a systematic review and meta-analysis of published and unpublished data for 603 838 individuals. Lancet 2015; 386: 1739–1746. |
| 321. | 12.21 | Nyberg ST, Fransson EI, Heikkilä K, et al. Job strain and cardiovascular disease risk factors: Meta-analysis of individual-participant data from 47,000 men and women. PLoSOne 2013; 8: e67323. |
| 322. | 12.22 | Georgiades A, Janszky I, Blom M, et al. Financial strain predicts recurrent events among women with coronary artery disease. Int J Cardiol 2009; 135: 175–183. |
| 323. | 12.23 | Pogosova N, Saner H, Pedersen SS, Cupples ME, McGee H, Hofer S, Doyle F,Schmid JP, von Kanel R. Psychosocial aspects in cardiac rehabilitation: from theoryto practice. A position paper from the Cardiac Rehabilitation Section of the EuropeanAssociation of Cardiovascular Prevention and Rehabilitation of the EuropeanSociety of Cardiology. Eur J Prev Cardiol 2015; 22: 1290–1306. |
| 324. | 12.24 | Погосова НВ, Колтунов ИЕ, Юферева ЮМ. Тревожные расстройства в кардиологической практике: состояние проблемы. Российский кардиологический журнал 2010; 5: 98-102. |
| 325. | 12.25 | Roest AM, Martens EJ, Denollet J, et al. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: A meta- analysis. Psychosom Med 2010; 72: 563–569. |
| 326. | 12.26 | Smoller JW, Pollack MH, Wassertheil-Smoller S, Jackson RD, ObermanA,Wong ND, Sheps D. Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women’s Health Initiative Observational Study. Arch Gen Psychiatry 2007; 64: 1153– 1160. |
| 327. | 12.27 | Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, Freedland KE, Jaffe AS, Leifheit-Limson EC, Sheps DS, Vaccarino V, Wulsin L. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014; 129: 1350–1369. |
| 328. | 12.28 | Погосова ГВ. Депрессия — фактор риска развития ишемической болезни сердца и предиктор коронарной смерти: 10 лет научного поиска. Кардиология 2012; 12: 6 -13. |
| 329. | 12.29 | Kamphuis MH, Kalmijn S, Tijhuis MAR, et al. Depressive symptoms as risk factor of cardiovascular mortality in older European men: the Finland, Italy and Netherlands Elderly (Fine) study. Eur J Cardiovasc Prev Rehabil 2006; |
| | | 13: 199-206. |
| 330. | 12.30 | De Miranda Azevedo R, Roest AM, Hoen PW, et al. Cognitive/affective and somatic/affective symptoms of depression in patients with heart disease and their association with cardiovascular prognosis: A meta-analysis. Psychol Med 2014; 27: 1–15. |
| 331. | 12.31 | Van Melle JP, de Jonge P, Spijkerman TA et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: A meta analysis. Psychosom Med 2004; 66: 814– 822. |
| 332. | 12.32 | Nicholson A, Kuper H and Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: A meta-analysis of 6362 events among 146 538 participant in 54 observational studies. Eur Heart J 2006; 27: 2763–2774 |
| 333. | 12.33 | Ziegelstein RC, Fauerbach JA, Stevens SS, et al. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 2000; 160: 1818– 1823. |
| 334. | 12.34 | Doyle F, Rohde D, Rutkowska A, et al. Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with coronary heart disease: 1990–2013. Psychosom Med 2014; 76: 44– 57. |
| 335. | 12.35 | DiMatteo MR, Lepper HS and Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101–2107. |
| 336. | 12.36 | Gehi A, Haas D, Pipkin S, et al. Depression and medication adherence in outpatients with coronary heart disease: Findings from the Heart and Soul Study. Arch Intern Med 2005; 165: 2508–2513. |
| 337. | 12.37 | Cohen BE, Panguluri P, Na B, et al. Psychological risk factors and the metabolic syndrome in patients with coronary heart disease: Findings from the Heart and Soul Study. Psychiatry Res 2010; 175: 133–137. |
| 338. | 12.38 | Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001; 104: 2024– 2028. |
| 339. | 12.39 | Taylor CB, Conrad A, Wilhelm FH, et al. Psychophysiological and cortisol responses to psychological stress in depressed and nondepressed older men and women with elevated cardiovascular disease risk. Psychosom Med 2006; 68: 538–546. |
| 340. | 12.40 | Shimbo D, Child J, Davidson K, et al. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol 2002; 89: 331–333. |
| 341. | 12.41 | Wittstein IS. Depression, anxiety, and platelet reactivity in patients with coronary heart disease. Eur Heart J 2010; 31: 1573–1582. |
| 342. | 12.42 | Austin AW, Wissmann T and von Kanel R. Stress and hemostasis: An update. SeminThrombHemost 2013; 39: 902–912. |
| 343. | 12.43 | Severus WE, Littman AB and Stoll AL. Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harv Rev Psychiatry 2001; 9: 280–293. |
| 344. | 12.44 | McNamara RK. Membrane omega-3 Fatty Acid deficiency as a preventable risk factor for comorbid coronary heart disease in major depressive disorder. Cardiovasc Psychiatry Neurol 2009; 2009: 362795. |
| 345. | 12.45 | Broadley AJ, Korszun A, Jones CJ, et al. Arterial endothelial function is impaired in treated depression. Heart 2002; 88: 521–523. |
| 346. | 12.46 | Sherwood A, Hinderliter AL, Watkins LL, et al. Impaired endothelial function in coronary heart disease patients with depressive symptomatology. J Am CollCardiol 2005; 46: 656–659. |
| 347. | 12.47 | Sheps DS, McMahon RP, Becker L et al. Mental-stress induced ischemia and all-cause mortality in patients with coronary artery disease: Results from the Psychophysiological Investigations of Myocardial Ischemia study. Circulation 2002; 105: 1780–1784. |
| 348. | 12.48 | Boyle SH, Samad Z, Becker RC, et al. Depressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart disease. Psychosom Med 2013; 75: 822–831. |
| 349. | 12.49 | Lesperance F, Frasure-Smith N, Theroux P, et al. The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatry 2004; 161: 271–277. |
| 350. | 12.50 | Empana JP, Sykes DH, Luc G, et al. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2005; 111: 2299–2305. |
| 351. | 12.51 | Rosengren A, Hawken S, Ounpuu S, et al, for the INTERHEART investigators. Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 953-962 |
| 352. | 12.52 | Albus C, Jordan J, Herrmann-Lingen C. Screening for psychosocial risk factors in patients with coronary heart disease-recommendations for clinical practice. Eur J Cardiovasc Prev Rehabil 2004; 11: 75–79. |
| 353. | 12.53 | Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, Freedland KE, Jaffe AS, Leifheit-Limson EC, Sheps DS, Vaccarino V, Wulsin L. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014; 129: 1350–1369. |
| 354. | 12.54 | Zigmond AS, Snaith RP. Hospital Anxiety and Depression Scale. Acta Psychiat Scand 1983; 67: 361– 370. |
| 355. | 12.55 | Погосова НВ, Довженко ТВ, Бабин АГ, Курсаков АА, Выгодин ВА. Русскоязычная версия опросников PHQ-2 И 9: чувствительность и специфичность при выявлении депрессии у пациентов общемедицинской амбулаторной практики. Кардиоваскулярная терапия и профилактика 2014;13(3): 18-24. |
| 356. | 12.56 | Whalley B, Thompson DR, Taylor RS. Psychological interventions for coronary heart disease: cochrane systematic review and meta-analysis. Int J Behav Med 2014; 21: 109–121. |
| 357. | 12.57 | Rutledge T, Redwine LS, Linke SE, Mills PJ. A meta-analysis of mental |
| | | health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med 2013; 75: 335–349. |
| 358. | 12.58 | Huffman JC, Mastromauro CA, Beach SR, Celano CM, DuBois CM, Healy BC, Suarez L, Rollman BL, Januzzi JL. Collaborative care for depression and anxiety disorders in patients with recent cardiac events: the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized clinical trial. JAMA Intern Med 2014; 174: 927–935. |
| 359. | 12.59 | Stewart JC, Perkins AJ, Callahan CM. Effect of collaborative care for depression on risk of cardiovascular events: data from the IMPACT randomized controlled trial. Psychosom Med 2014;76:29–37. |
| 360. | 12.60 | Glozier N, Christensen H, Naismith S, Cockayne N, Donkin L, Neal B, Mackinnon A, Hickie I. Internet-delivered cognitive behavioural therapy for adults with mild to moderate depression and high cardiovascular disease risks: a randomized attention-controlled trial. PLoS One 2013; 8: e59139. |
| 361. | 12.61 | Albus C, Ladwig KH, Herrmann-Lingen C. [Psychocardiology: clinically relevant recommendations regarding selected cardiovascular diseases]. Dtsch Med Wochenschr 2014; 139: 596–601. |
| 362. | 12.62 | Chandola T, Britton A, Brunner E, Hemingway H, Malik M, Kumari M, Badrick E, Kivimaki M, Marmot M. Work stress and coronary heart disease: what are the mechanisms? Eur Heart J 2008; 29: 640–648. |
| 363. | 12.63 | Orth-Gomer K, Schneiderman N, Wang HX, Walldin C, Blom M, Jernberg T. Stress reduction prolongs life in women with coronary disease: the Stockholm Women’s Intervention Trial for Coronary Heart Disease (SWITCHD). Circ Cardiovasc Qual Outcomes 2009; 2: 25–32. |
| 364. | 12.64 | Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svardsudd K. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med 2011; 171: 134–140. |
| 365. | 12.65 | Lie I, Arnesen H, Sandvik L, Hamilton G, Bunch EH. Effects of a home-based intervention program on anxiety and depression 6 months after coronary artery bypass grafting: a randomized controlled trial. J Ppsychosom Res 2007; 62: 411–418. |
| 366. | 12.66 | Page T, Lockwood C, Conroy-Hiller T. Effectiveness of nurse-led cardiac clinics in adult patients with a diagnosis of coronary heart disease. Int J Evid Based Healthcare 2005; 3: 2–26. |
| 367. | 12.67 | Поздняков. Горбаченков АА, Поздняков ЮМ. Коронарный клуб. – М.. ЦПФС «Единение» 1999. 240c. |
| 368. | 12.68 | Hare DL, Toukhsati SR, Johansson P, Jaarsma P. Depression and cardiovascular disease: a clinical review. Eur Heart J 2014; 35: 1365-1372 |
| 369. | 12.69 | Оганов РГ, Ольбинская ЛИ, Смулевич АБ, Вейн АМ, Дробижев МЮ, Шальнова СА, Погосова ГВ и совт. Депрессии и расстройства депрессивного спектра в общемедицинской практике. Результаты программы КОМПАС. Кардиология 2004; 1: 48-54 |
| 370. | 12.70 | Чазов ЕИ, Оганов РГ, Погосова НВ, Шальнова СА, Ромасенко ЛВ, Щуров ДВ. Клинико-эпидемиологическая программа изучения депрессии в |
| | | кардиологической практике: у больных артериальной гипертонией и ишемической болезнью сердца (КООРДИНАТА): первые результаты многоцентрового исследования. Кардиология 2005; 11: 4-11 |
| 371. | 12.71 | Погосова НВ, Бойцов СА, Оганов РГ, Юферева Ю.М., Курсаков АА, Исакова СС, Аушева АК, Карпова АВ, Арутюнов АА, Василевский АС. Психосоциальные факторы риска у больных АГ/ИБС: первые результаты российского многоцентрового исследования КОМЕТА. Кардиология 2018 (в печати) |
| 372. | 12.72 | Погосова НВ, Оганов РГ, Бойцов СА, Аушева АК, Соколова ОЮ, Курсаков АА, Поздняков ЮМ, Салбиева АО, Лельчук ИН, Гусарова ТА, Гомыранова НВ, Карпова АВ, Елисеева НА, Ахмедова ЭБ, Бедейникова КК, Ковригина МН. Психосоциальные факторы и качество жизни у пациентов с ИБС: результаты российской части международного многоцентрового исследования EUROASPIRE IV. Кардиоваскулярная терапия и профилактика 2017 (в печати) |
| 373. | 12.73 | Pogosova N, Kotseva K, De Bacquer D, von Känel R, De Smedt D, Bruthans J, Dolzhenko M; EUROASPIRE Investigators. Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: Results from the EUROASPIRE IV survey. A registry from the European Society of Cardiology. Eur J Prev Cardiol 2017 ; 24(13): 1371-1380. doi:10.1177/2047487317711334. Epub 2017 May 23. |
| 374. | 12.74 | Watkins LL, Koch GG, Sherwood A, Blumenthal JA, Davidson JR, O’Connor C, Sketch MH. Association of anxiety and depression with all-cause mortality in individuals with coronary heart disease. J Am Heart Assoc 2013; 2: e000068. |
| 375. | 12.75 | Albus C. Psychosocial risk factors: time for action in lifelong prevention of coronary heart disease. European Journal of Preventive Cardiology 2017; 24(13): 1369–1370. |
| 376. | 12.76 | Dickens C, Cherryington A, Adeyemi I, Roughley K, Bower P, Garrett C, Bundy C, Coventry P. Characteristics of psychological interventions that improve depression in people with coronary heart disease: a systematic review and meta-regression. Psychosom Med 2013; 75: 211–221. |
| 377. | 12.77 | Погосова ГВ, Калинина АМ, Спивак ЕЮ, Назаркина ВА. Эффективность образовательной профилактической технологии у больных стабильной стенокардией в амбулаторных условиях. Кардиология 2008; 7: 4-9. |
| 378. | 12.78 | Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Smith PJ, Hoffman BM, O’Hayer CV, Mabe S, Johnson J, Doraiswamy PM, Jiang W, Schocken DD, Hinderli AL. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol 2012; 60: 1053–1063 |
| 379. | 12.79 | Glassman AH, Bigger JT Jr, Gaffney M.Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants. Arch Gen Psychiatry 2009; 66(9): 1022-9. |
| 380. | 12.80 | Bekke-Hansen S1, Trockel M, Burg MM, Taylor CB. Depressive symptom dimensions and cardiac prognosis following myocardial infarction: results |
| | | from the ENRICHD clinical trial. Psychol Med 2012; 42(1): 51-60. |
| 381. | 12.81 | Roest AM, Carney RM, Freedland KE, Martens EJ, Denollet J, de Jonge P. Changes in cognitive versus somatic symptoms of depression and event- free survival following acute myocardial infarction in the Enhancing Recovery In Coronary Heart Disease (ENRICHD) study. J Affect Disord 2013; 149(1-3): 335-41. |
| 382. | 12.82 | Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746–758. |
| | | 13. Биомаркеры, определяемые в крови и моче |
| 383. | 13.1 | Gilstrap LG, Wang TJ. Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem 2012; 58: 72–82. |
| 384. | 13.2 | Ioannidis JP, Tzoulaki I. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. Circ Res 2012; 110: 658–662. |
| 385. | 13.3 | Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Bjorkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D’Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engstrom G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jorgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil- Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367: 1310–1320. |
| 386. | 13.4 | Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC Jr, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Nishimura R, Ohman EM, Page RL, Stevenson WG, Tarkington LG, Yancy CW. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am CollCardiol 2010; 56: e50–e103. |
| 387. | 13.5 | Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP. Bias in associations of emerging biomarkers with cardiovascular disease. JAMA Intern Med 2013; 173: 664–671. |
| 388. | 13.6 | Kooter AJ, Kostense PJ, Groenewold J, Thijs A, Sattar N, Smulders YM. Integrating information from novel risk factors with calculated risks: the |
| | | critical impact of risk factor prevalence. Circulation 2011; 124: 741–745. |
| 389. | 13.7 | Wurtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, Ghorbani A, Artati A, Wang Q, Tiainen M, Kangas AJ, Kettunen J, Kaikkonen J, Mikkila V, Jula A, Kahonen M, Lehtimaki T, Lawlor DA, Gaunt TR, Hughes AD, Sattar N, Illig T, Adamski J, Wang TJ, Perola M, Ripatti S, Vasan RS, Raitakari OT, Gerszten RE, Casas JP, Chaturvedi N, Ala-Korpela M, Salomaa V. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 2015; 131: 774–85. |
| 390. | 13.8 | Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation 2012; 126: 1110– 1120. |
| | | 14. Другие маркеры риска (генетика) |
| 391. | 14.1 | Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898–904. |
| 392. | 14.2 | Benvenisty, Marenberg ME, Risch N, Berkman LF et al. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330(15): 1041-6. |
| 393. | 14.3 | Mayer B, Erdmann J and Schunkert H. Genetics and heritability of coronary artery disease and myocardial infarction. Clin Res Cardiol 2007; 96(1): 1-7. |
| 394. | 14.4 | Banerjee A. A review of family history of cardiovascular disease: risk factor and research tool. Int J ClinPract 2012;66:536-543. |
| 395. | 14.5 | Bachmann JM, Willis BL, Ayers CR, Khera A, Berry JD. Association between family and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study. Circulation 2012; 125: 3092- 3098. |
| 396. | 14.6 | Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol 2013; 33: 2261–2266. |
| 397. | 14.7 | Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, Guiducci C, Perola M, Jula A, Sinisalo J, Lokki ML, Nieminen MS, Melander O, Salomaa V, Peltonen L, Kathiresan S. A multilocusgenetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet 2010; 376: 1393–1400. |
| 398. | 14.8 | Sivapalaratnam S, Boekholdt SM, Trip MD, Sandhu MS, Luben R, Kastelein JJ, Wareham NJ, Khaw KT. Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart 2010; 96: 1985–1989. |
| 399. | 14.9 | Veronesi G, Gianfagna F, Giampaoli S, Chambless LE, Mancia G, Cesana G, Ferrario MM. Improving long-term prediction of first cardiovascular event: the contribution of family history of coronary heart disease and social status. Prev Med 2014; 64:75–80. |
| 400. | 14.10 | Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012; 308: 788–795. |
| 401. | 14.11 | Hughes MF, Saarela O, Stritzke J, Kee F, Silander K,Klopp N, Kontto J, |
| | | Karvanen J, Willenborg C, Salomaa V, Virtamo J, Amouyel P, Arveiler D, Ferrieres J, Wiklund PG, Baumert J, Thorand B, DiemertP, Tregouet DA, Hengstenberg C, Peters A, Evans A, Koenig W, Erdmann J, Samani NJ, Kuulasmaa K, Schunkert H. Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts. PLoS One 2012; 7: e40922. |
| 402. | 14.12 | Dai X, Wiernek S, Evans JP, Runge MS. Genetics of coronary artery disease and myocardial infarction World J Cardiol 2016; 8(1): 1-23. |
| 403. | 14.13 | Roberts R. Genetics of coronary artery disease. Circ Res 2014; 114: 1890– 1903. |
| 404. | 14.14 | CARDIoGRAMplusC4DConsortium, Deloukas P, Kanoni S et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013; 45: 25–33. |
| 405. | 14.15 | Ganna A, Magnusson PK, Pedersen NL, de Faire U, Reilly M, Arnlov J, Sundstrom J, Hamsten A, Ingelsson E. Multilocus genetic risk scores for coronary heart disease prediction. Arterioscl Thromb Vasc Biol 2013; 33: 2267–2272. |
| 406. | 14.16 | Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, Nordio F, Hyde CL, Cannon CP, Sacks FM, Poulter NR, Sever PS, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015; 385: 2264–2271. |
| 407. | 14.17 | Brautbar A, Pompeii LA, Dehghan A, Ngwa JS, Nambi V, Virani SS, Rivadeneira F, Uitterlinden AG, Hofman A, Witteman JC, Pencina MJ, Folsom AR, Cupples LA, Ballantyne CM, Boerwinkle E. A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies. Atherosclerosis 2012; 223: 421–426. |
| 408. | 14.18 | Bressler J, Folsom AR, Couper DJ, Volcik KA, Boerwinkle E. Genetic variants identifiedin a European genome-wide association study that were found to predict incident coronary heart disease in the atherosclerosis risk in communities study. Am J Epidemiol 2010; 171: 14–23. |
| 409. | 14.19 | Максимов ВН, Куликов ИВ, Орлов ПС, Гафаров ВВ, Малютина СК, Ромащенко АГ, Воевода МИ. Проверка взаимосвязи между девятью однонуклеотидными полиморфизмами и инфарктом миокарда на сибирской популяции. Вестник РАМН 2012; 5:24-29. |
| 410. | 14.20 | Усачева МА, Наседкина ТВ, Иконникова АЮ, Куликов АВ, Чудинов АВ, Лысов ЮП, Бондаренко ЕВ, Сломинский ПА, Шамалов НА, Шетова ИМ, Лимборская СА, Заседателев АС, Скворцова ВИ. Анализ ассоциации полиморфных маркеров генов ренин-ангиотензиновой системы и системы гемостаза с ишемическим инсультом среди русских Центральной России. Молекулярная Биология 2012; 46 (2): 192-199. |
| 411. | 14.21 | Singleton A, Erby LH, Foisie KV, Kaphingst KA. Informed choice in direct-to- consumer genetic testing (DTCGT) websites: a content analysis of benefits, risks, and limitations. J Genet Couns 2012; 21: 433–439. |
| 412. | 14.22 | Rodenhiser D, Mann M. Epigenetics and human disease: translating basic |
| | | biology into clinical applications. CMAJ2006; 174(3): 341-8. |
| 413. | 14.23 | Kelsey G, Feil R. New insights into establishment and maintenance of DNA methylation imprints in mammals. Philos Trans R Soc Lond B Biol Sci 2013; 368(1609): 20110336. doi: 10.1098/rstb.2011.0336. |
| 414. | 14.24 | Guay SP, Brisson D, Lamarche B, Marceau P, Vohl MC, Gaudet D, Bouchard L. DNA methylation variations at CETP and LPL gene promoter loci: new molecular biomarkers associated with blood lipid profile variability. Atherosclerosis 2013; 228: 413–420. |
| 415. | 14.25 | Wang X, Falkner B, Zhu H, Shi H, Su S, Xu X, Sharma AK, Dong Y, Treiber F, Gutin B, Harshfield G, Snieder H. A genome-wide methylation study on essential hypertension in young African American males. PLoS One 2013; 8: e53938. |
| 416. | 14.26 | Baccarelli A, Wright R, Bollati V, Litonjua A, Zanobetti A, Tarantini L, Sparrow D, Vokonas P, Schwartz J. Ischemic heart disease and stroke in relation to blood DNA methylation. Epidemiology 2010; 21: 819–828. |
| 417. | 14.27 | Киселева А.В., Жарикова А.А., Мешков А.Н. Влияние курения на статус метилирования дезоксирибонуклеиновой кислоты. Кардиоваскулярная терапия и профилактика 2015; 14(6): 73-77. |
| 418. | 14.28 | Mao Y, Mohan R, Zhang S, Tang X. MicroRNAs as pharmacological targets in diabetes. Pharmacol Res 2013;75: 37-47. |
| 419. | 14.29 | RivièreG, LienhardD, AndrieuT, VieauD, FreyBM, FreyFJ. Epigenetic regulation of somatic angiotensin-converting enzyme by DNA methylation and histone acetylation. Epigenetics 2011; 6(4): 478-89. |
| 420. | 14.30 | Киселева АВ, Стражеско ИД, Карамнова НС и соавт. Динамика эпигенетических маркеров ожирения при диетологической коррекции направленной на снижение массы тела. Профилактическая медицина 2015; 18(5): 63-69. |
| 421. | 14.31 | Milagro FI, Campion J, Cordero P, et al. A dual-epigenomic approach for the search of obesity biomarkers: DNA methylation in relation to diet- induced weight loss. FASEB J 2011; 25: 1378–1389. |
| 422. | 14.32 | AbiKhalil C. The emerging role of epigenetics in cardiovascular disease. Ther Adv Chron Dis 2014; 5(4): 178-187. |
| 423. | 14.33 | Zineh I, Pacanowski MA. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration. Pharmacotherapy 2011; 31(8):729-35. |
| 424. | 14.34 | Johnson JA, Cavallari LH. Pharmacogenetics and Cardiovascular Disease— Implications for Personalized Medicine. Touyz RM, et al. Pharmacological Reviews 2013; 65(3): 987-1009. |
| 425. | 14.35 | Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. ClinPharmacolTher 2011; 90(4): 625-9 |
| 426. | 14.36 | Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest |
| | | Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2): 7S-47. |
| 427. | 14.37 | Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am CollCardiol 2010; 56(4):321-41. |
| | | 15. Методы неинвазивной диагностики субклинического поражения сосудов |
| 428. | 15.1 | Haberl R, Becker A, Leber A, Knez A, Becker C, Lang C, Bruning R, Reiser M, Steinbeck G. Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: results of 1,764 patients. J Am Coll Cardiol 2001; 37: 451-457. |
| 429. | 15.2 | Marwan M, Ropers D, Pflederer T, Daniel WG, Achenbach S. Clinical characteristics of patients with obstructive coronary lesions in the absence of coronary calcification: an evaluation by coronary CT angiography. Heart 2009; 95: 1056-1060. |
| 430. | 15.3 | Hecht HS, Superko HR. Electron beam tomography and National Cholesterol Education Program guidelines in asymptomatic women. J Am Coll Cardiol 2001; 37:1506-1511. |
| 431. | 15.4 | Hadamitzky M, Freissmuth B, Meyer T, Hein F, Kastrati A, Martinoff S, Schomig A, Hausleiter J. Prognostic value of coronary computed tomographic angiography for prediction of cardiac events in patients with suspected coronary artery disease. JACC Cardiovasc Imaging 2009; 2: 404– 411. |
| 432. | 15.5 | Van Werkhoven JM, Gaemperli O, Schuijf JD, Jukema JW, Kroft LJ, Leschka S, Alkadhi H, Valenta I, Pundziute G, de Roos A, van der Wall EE, Kaufmann PA, Bax JJ. Multislice computed tomography coronary angiography for risk stratification in patients with an intermediate pretest likelihood. Heart 2009; 95: 1607-1611. |
| 433. | 15.6 | Peters SA, den Ruijter HM, Bots ML, Moons KG. Improvements in risk stratification for the occurrence of cardiovascular disease by imagiing subclinical atherosclerosis: a systematic review. Heart 2012; 98: 177–184. |
| 434. | 15.7 | O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14 – 22. |
| 435. | 15.8 | Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol 1997; 146: 483- 494. |
| 436. | 15.9 | Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, Engstrom G, Evans GW, de Graaf J, Grobbee DE, Hedblad B, Hofman A, Holewijn S, Ikeda A, Kavousi M, Kitagawa K, Kitamura A, Koffijberg H, Lonn EM, Lorenz MW, Mathiesen EB, Nijpels G, Okazaki S, O’Leary DH, Polak JF, Price JF, Robertson C, Rembold CM, Rosvall M, Rundek T, Salonen JT, Sitzer |
| | | M, Stehouwer CD, Witteman JC, Moons KG, Bots ML. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta analysis. JAMA 2012; 308: 796-803. |
| 437. | 15.10 | Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21. |
| 438. | 15.11 | McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, Chan C, Martin GJ, Schneider J, Pearce WH, Taylor LM, Clark E. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med 2002; 136: 873–883. |
| 439. | 15.12 | Fowkes FG, Murray GD, Newman AB, Lee RJ. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008; 300: 197–208. |
| 440. | 15.13 | Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303: 841 – 848. |
| 441. | 15.14 | Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Volzke H, Tuomainen TP, Sander D, Plichart M, Catapano AL, Robertson CM, Kiechl S, Rundek T, Desvarieux M, Lind L, Schmid C, DasMahapatra P, Gao L, Ziegelbauer K, Bots ML, Thompson SG. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012; 379: 2053 – 2062. |
| 442. | 15.15 | Tinana A, Mintz GS, Weissman NJ. Volumetric intravascular ultrasound quantifi- cation of the amount of atherosclerosis and calcium in nonstenotic arterial segments. Am J Cardiol 2002; 89: 757-760. |
| 443. | 15.16 | Schmermund A, Schwartz RS, Adamzik M, Sangiorgi G, Pfeifer EA, Rumberger JA, Burke AP, Farb A, Virmani R. Coronary atherosclerosis in unheralded sudden cor- onary death under age 50: histopathologic comparison with ‘healthy’ subjects dying out of hospital. Atherosclerosis 2001; 155: 499 – 508. |
| 444. | 15.17 | Burke AP, Kolodgie FD, Farb A, Weber D, Virmani R. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation 2002; 105: 297-303. |
| 445. | 15.18 | Silber S. Comparison of spiral and electron beam tomography in the evaluation of coronary calcification in asymptomatic persons. Int J Cardiol 2002; 82: 297-298; author reply 299. |
| 446. | 15.19 | Knez A, Becker A, Leber A, et al. Relation of coronary calcium scores by electron beam tomography to obstructive disease in 2,115 symptomatic patients. Am J Cardiol 2004; 93: 1150 –2 |
| 447. | 15.20 | Gibson AO, Blaha MJ, Arnan MK, Sacco RL, Szklo M, Herrington DM, Yeboah J. Coronary artery calcium and incident cerebrovascular events in an asymptomatic cohort. The MESA Study. JACC Cardiovasc Imaging 2014; 7: 108-1115. |
| 448. | 15.21 | Fernandez-Friera L, Penalvo JL, Fernandez-Ortiz A, Ibanez B, Lopez-Melgar B, Laclaustra M, Oliva B, Mocoroa A, Mendiguren J, Martinez de Vega V, Garcia L, Molina J, Sanchez-Gonzalez J, Guzman G, Alonso-Farto JC, Guallar E, Civeira F, Sillesen H, Pocock S, Ordovas JM, Sanz G, Jimenez-Borreguero |
| | | LJ, Fuster V. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: the PESA (Progression of Early Subclinical Atherosclerosis) study. Circulation 2015; 131: 2104 – 2113. |
| 449. | 15.22 | Nasir K, Bittencourt MS, Blaha MJ, Blankstein R, Agatson AS, Rivera JJ, Miemdema MD, Sibley CT, Shaw LJ, Blumenthal RS, Budoff MJ, Krumholz 15.23HM. Im- plications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol man- agement guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Car- diol 2015;66:1657–1668. |
| 450. | 15.23 | Гуревич ВС. Современные представления о патогенезе атеросклероза. Болезни сердца и сосудов 2006; 4: 4-8. |
| 451. | 15.24 | Кузнецов АН. Мультифокальный атеросклероз. Современные принципы лечения мультифокального атеросклероза. Вестник Национального медико-хирургического центра имени Н.И.Пирогова; 2008: 3 (2) 78-83. |
| 452. | 15.25 | Tarantini G, Napodano M, Gasparetto N, et al. Impact of multivessel coronary artery disease on early ischemic injury, late clinical outcome, and remodeling in patients with acute myocardial infarction treated by primary coronary angioplasty. Coron Artery Dis; 2010; 21(2): 78-86. |
| 453. | 15.26 | Janzen J. The microscopic transitional zone between elastic and muscular arteries. Arch Mal Coeur Vaiss 2004; 97: 909-14. |
| 454. | 15.27 | Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 2012; 34(4): 290-6. |
| 455. | 15.28 | Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima- Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008; 21: 93–111. |
| 456. | 15.29 | Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318 – 1327. |
| 457. | 15.30 | Van Bortel LM, Laurent S, Boutouyrie P et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid- femoral pulse wave velocity. J Hypertens 2012; 30(3): 445–448. |
| 458. | 15.31 | The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology 2013 Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34 (28): 2159-2219 |
| 459. | 15.32 | Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP. Bias in associations of emerging biomarkers with cardiovascular disease. JAMA Intern Med 2013; 173: 664–671. |
| 460. | 15.33 | U.S. Preventive Services Task Force. Using nontraditional risk factors in |
| | | coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;151(7): 474-82. |
| 461. | 15.34 | Taylor HA, Penman AD, Han H, Dele-Michael A, Skelton TN, Fox ER, Benjamin EJ, Arnett DK, Mosley TH Jr. Left ventricular architecture and survival in African-Americans free of coronary heart disease (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2007; 99: 1413-1420. |
| 462. | 15.35 | Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, Poisa P, Rizzoni D, Castellano M, Agabiti-Rosei E. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004; 43: 731 – 738. |
| 463. | 15.36 | Widmer RJ, Lerman A. Endothelial dysfunction and cardiovascular disease.Global Cardiology Science & Practice 2014; 2014(3) :291-308. doi:10.5339/gcsp.2014.43. |
| 464. | 15.37 | Иванова ОВ, Рогоза АН, Балахонова ТВ, Соболева ГН, Атьков ОЮ, Карпов ЮА. Определение чувствительности плечевой артерии к напряжению сдвига на эндотелии как метод оценки состояния эндотелийзависимой вазодилатации с помощью ультразвука высокого разешения у больных с артериальной гипертонией. Кардиология 1998; 8: 37-40. 268. |
| 465. | 15.38 | Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999; 34: 631-638. |
| 466. | 15.39 | Hamburg N, Keyes, M.G. Larson et al. Cross-Sectional Relations of Digital Vascular Function to Cardiovascular Risk Factors in the Framingham Heart Study. Circulation 2008; 117: 2467-2474. |
| 467. | 15.40 | Matsuzawa Y, Li J, Aoki T, et al. Predictive value of endothelial function by non-invasive peripheral arterial tonometry for coronary artery disease.Coronary artery disease 2015; 26(3): 231-238. |
| | | 16.1 Фибриляция предсердий |
| 468. | 16.1.1 | Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38): 2893-2962. |
| 469. | 16.1.2 | Ревишвили АШ, Рзаев ФГ, Горев МВ, Нардая ШГ. Клинические Рекомендации: «Диагностика и лечение фибрилляции предсердий» Рекомендации разработаны экспертами Всероссийского Научного Общества специалистов по клинической электрофизиологии, Аритмологии и электрокардиостимуляции (ВНОА) в сотрудничестве с Российским Кардиологическим обществом (РКО) и Ассоциацией сердечно‐сосудистых хирургов России (АССХ). Москва 2017. |
| 470. | 16.1.3 | O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, Rao-Melacini |
| | | P, Zhang X, Pais P, Agapay S, Lopez-Jaramillo P, Damasceno A, Langhorne P, McQueen MJ, Rosengren A, Dehghan M, Hankey GJ, Dans AL, Elsayed A, Avezum A, Mondo C, Diener HC, Ryglewicz D, Czlonkowska A, Pogosova N, Weimar C, Iqbal R, Diaz R, Yusoff K, Yusufali A, Oguz A, Wang X, Penaherrera E, Lanas F, Ogah OS, Ogunniyi A, Iversen HK, Malaga G, Rumboldt Z, Oveisgharan S, Al Hussain F, Magazi D, Nilanont Y, Ferguson J, Pare G, Yusuf S; INTERSTROKE investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016; 388(10046): 761-75. |
| 471. | 16.1.4 | Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516–521 |
| 472. | 16.1.5 | Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 2007; 28(22): 2803-17. |
| 473. | 16.1.6 | Nyrnes A, Mathiesen EB, Njolstad I, Wilsgaard T, Lochen ML. Palpitations are predictive of future atrial fibrillation. An 11-year follow-up of 22,815 men and women: the Tromso Study. Eur J Prev Cardiol 2013; 20: 729-736. |
| 474. | 16.1.7 | Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S, Lip GY, Narkiewicz K, Parati G, Redon J, Schmieder R, Tsioufis C, Mancia G. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension. J Hypertens 2012; 30: 239–252. |
| 475. | 16.1.8 | Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by 476 representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur Heart J 2016 doi:10.1093/eurheartj/ehw106. |
| 476. | 16.1.9 | Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263–272. |
| 477. | 16.1.10 | Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation 2008; 118: 800–807. |
| 478. | 16.1.11 | Mont L, Sambola A, Brugada J, Vacca M, Marrugat J, Elosua R, Pare C, Azqueta M, Sanz G. Long-lasting sport practice and lone atrial fibrillation. Eur Heart J 2002; 23: 477–482. |
| 479. | 16.1.12 | Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis. Europace 2009; 11: 1156-1159. |
| 480. | 16.1.13 | Thelle DS, Selmer R, Gjesdal K, Sakshaug S, Jugessur A, Graff-Iversen S, Tverdal A, NystadW. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women. Heart 2013; 99: 1755–1760. |
| 481. | 16.1.14 | Andersen K, Farahmand B, Ahlbom A, Held C, Ljunghall S, Michaelsson K, Sundstrom J. Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. Eur Heart J 2013; 34: 3624–3631. |
| 482. | 16.1.15 | Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M. Lone atrial fibrillation in vigorously exercising middle aged men: case-control study. BMJ 1998; 316: 1784–1785. |
| 483. | 16.1.16 | Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol 2009; 103: 1572–1577. |
| 484. | 16.1.17 | Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E, Nadal M, Andreu D, Vidal B, Sitges M, Brugada J. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace 2010; 12: 30–36. |
| 485. | 16.1.18 | Koopman P, Nuyens D, Garweg C, La Gerche A, De Buck S, Van Casteren L, Alzand B, Willems R, Heidbuchel H. Efficacy of radiofrequency catheter ablation in athletes with atrial fibrillation. Europace 2011; 13: 1386–1393. |
| 486. | 16.1.19 | Бокерия ЛА, Ревишвили АШ, Оганов РГ и соавт. Клинические рекомендации (ВНОА, ВНОК, АССХ) по проведению электрофизиологических исследований, катетерной аблации и применения имплантируемых антиаритмических устройств. Москва, 2009. «Асконлайн». C. 237-303. |
| 487. | 16.1.20 | Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P, Calzolari M, Solano A, Baroffio R, Gaggioli G. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004; 351: 2384–2391. |
| 488. | 16.1.21 | Lowres N, Neubeck L, Freedman SB, Briffa T, Bauman A, Redfern J. Lifestyle risk reduction interventions in atrial fibrillation: a systematic review. Eur J Prev Cardiol 2012; 19: 1091–1100. |
| 489. | 16.1.22 | Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, Lau DH, Sanders P.Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol 2015; 65(20): 2159-69. |
| 490. | 16.1.23 | Middeldorp ME, Pathak RV, Mehta A et al. Prevention and regressive effect of weight loss and risk factor modification on atrial fibrillation (REVERSE-AF). Heart Rhythm Society 2016 Scientific Sessions 2016; San Francisco CA. Abstract AB21-05 |
| 491. | 16.1.24 | Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Hendriks JM, Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study. J Am Coll Cardiol 2015; 66(9): 985-96. |
| 492. | 16.1.25 | Van Gelder IC, et al. Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure, the RACE 3 study. |
| | | European Society of Cardiology Congress 2017. Abstract 2128. |
| 493. | 16.1.26 | Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol 2013; 28(1): 7-18. |
| 494. | 16.1.27 | Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, Krane V, Macfarlane PW; PROSPER Executive. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 2011; 342: d1250. |
| 495. | 16.1.28 | Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL, Authors/Task Force Members; 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. EurHeart J 2016; 37(39): 2999-3058. |
| | | 16.2 ЦВБ |
| 496. | 16.2.1 | Thrift AG, Thayabaranathan T, Howard G, Howard VJ, Rothwell PM, Feigin VL, Norrving B, Donnan GA, Cadilhac DA. Global stroke statistics. Int J Stroke 2017; 12(1): 13-32. |
| 497. | 16.2.2 | Benjamin EJ, Blaha MJ, Chiuve SE et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation 2017; 135: 146–603. |
| 498. | 16.2.3 | Feigin VL, Norrving B, Mensah GA. Global Burden of Stroke. Circulation Research 2017; 120: 439-448 |
| 499. | 16.2.4 | Демографический ежегодник России. 2015: Стат. сб.Росстат. M. 2015. 263c. |
| 500. | 16.2.5 | Погосова НВ, Оганов РГ, Суворов СВ. Почему в Москве смертность от сердечно-сосудистых заболеваний ниже, чем в других регионах Российской Федерации? Кардиоваскулярная терапия и профилактика 2015; 14(2): 4–12. |
| 501. | 16.2.6 | Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-81 |
| 502. | 16.2.7 | O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, Rao-Melacini P, Zhang X, Pais P, Agapay S, Lopez-Jaramillo P, Damasceno A, Langhorne P, McQueen MJ, Rosengren A, Dehghan M, Hankey GJ, Dans AL, Elsayed A, Avezum A, Mondo C, Diener HC, Ryglewicz D, Czlonkowska A, Pogosova N, Weimar C, Iqbal R, Diaz R, Yusoff K, Yusufali A, Oguz A, Wang X, Penaherrera E, Lanas F, Ogah OS, Ogunniyi A, Iversen HK, Malaga G, Rumboldt Z, Oveisgharan S, Al Hussain F, Magazi D, Nilanont Y, Ferguson J, Pare G, Yusuf S; INTERSTROKE investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016; 388(10046): 761-75. |
| 503. | 16.2.8 | Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, |
| | | Mensah GA, Norrving B, Shiue I, Ng M, Estep K, Cercy K, Murray CJL, Forouzanfar MH; Global Burden of Diseases, Injuries and Risk Factors Study 2013 and Stroke Experts Writing Group. Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol 2016; 15(9): 913- 924. doi: 10.1016/S1474-4422(16)30073-4. Epub 2016 Jun 9. |
| 504. | 16.2.9 | Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD,Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160–2236. |
| 505. | 16.2.10 | Steiner T, Al-Shahi Salman R, Beer R, Christensen H, Cordonnier C, Csiba L, Forsting M, Harnof S, Klijn CJM, Krieger D, Mendelow AD, Molina C, Montaner J, Overgaard K, Petersson J, Roine RO, Schmutzhard E, Schwerdtfeger K, Stapf C, Tatlisumak T, Thomas BM, Toni D, Unterberg A, Wagner M. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke 2014;9: 840–855. |
| 506. | 16.2.11 | Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis 2013; 35: 93– 112. |
| 507. | 16.2.12 | Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, deVeber G, Ferro JM, Tsai FY. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 1158–1192. |
| 508. | 16.2.13 | Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, Deruyter F, Eng JJ, Fisher B, Harvey RL, Lang CE, MacKay-Lyons M, Ottenbacher KJ, Pugh S, Reeves MJ, Richards LG, Stiers W, Zorowitz RD; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Quality of Care and Outcomes Research.Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2016; 47(6): 98- 169. doi: 10.1161/STR.0000000000000098. Epub 2016 May 4. |
| 509. | 16.2.14 | Zhao J, Zhang X, Dong L, Wen Y, Cui L. The many roles of statins in ischemic stroke. Current Neuropharmacology 2014; 12(6): 564-574. doi:10.2174/1570159X12666140923210929. |
| 510. | 16.2.15 | Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high risk conditions. Lancet 2004; 363: 757–767. |
| 511. | 16.2.16 | Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. High- dose atorvastatin after stroke or transient ischemic attack. N Engl J Med |
| | | 2006; 355: 549–559. |
| 512. | 16.2.17 | Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, Donner A, Mamdani M, Douketis JD, Arima H, Chalmers J, MacMahon S, Tirschwell DL, Psaty BM, Bushnell CD, Aguilar MI, Capampangan DJ, Werring DJ, De Rango P, Viswanathan A, Danchin N, Cheng CL, Yang YH, Verdel BM, Lai MS, Kennedy J, Uchiyama S, Yamaguchi T, Ikeda Y, Mrkobrada M. Statins and intracerebral hemorrhage: collaborative systematic review and meta- analysis. Circulation 2011;124: 2233-2242. |
| 513. | 16.2.18 | Bath PM, Krishnan K. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev 2014; 10: CD000039. doi:10.1002/14651858.CD000039.pub3 |
| 514. | 16.2.19 | Bath PM, Woodhouse L, Scutt P, Krishnan K, Wardlaw JM, Bereczki D, Sprigg N, Berge E, Beridze M, Caso V, Chen C, Christensen H, Collins R, El Etribi A, Laska AC, Lees KR, Ozturk S, Phillips S, Pocock S, Asita de Silva H, Szatmari S, Utton S. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial factorial randomised controlled trial. Lancet 2015; 385: 617-628. |
| 515. | 16.2.20 | Jusufovic M, Sandset EC, Bath PMW, et al. Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis. Int J Stroke 2015; 10: 354-359. doi:10.1111/ijs.12418 |
| 516. | 16.2.21 | Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J. Rapid blood pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013; 368: 2355–2365. |
| 517. | 16.2.22 | Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, Moy CS, Silbergleit R, Steiner T, Suarez JI, Toyoda K, Wang Y, Yamamoto H, Yoon BW; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. N Engl J Med 2016;375(11): 1033-43. doi: 10.1056/NEJMoa1603460. Epub 2016 Jun 8. |
| 518. | 16.2.23 | Jauch EC, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44:870–947. |
| 519. | 16.2.24 | Intercollegiate Stroke Working Party. National clinical guideline for stroke, 4th edn. Royal College of Physicians 2012. |
| 520. | 16.2.25 | Hacke W, Ringleb PA, Bousser MG, et al. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008—the European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee. Cerebrovasc Dis 2008;25: 457–507. doi:10.1159/000131083 |
| 521. | 16.2.26 | Appleton JP, Sprigg N, Bath PM. Blood pressure management in acute stroke. Stroke and Vascular Neurology 2016; 1(2): 72-82; DOI: 10.1136/svn-2016-000020 |
| 522. | 16.2.27 | Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological |
| | | studies. BMJ 2009; 338: b1665. |
| 523. | 16.2.28 | PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358: 1033–1041. |
| 524. | 16.2.29 | Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker- Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): 2159-219. doi: 10.1093/eurheartj/eht151. |
| 525. | 16.2.30 | Epstein KA, Viscoli CM, Spence JD, Young LH, Inzucchi SE, Gorman M, Gerstenhaber B, Guarino PD, Dixit A, Furie KL, Kernan WN; IRIS Trial Investigators. Smoking cessation and outcome after ischemic stroke or TIA. Neurology 2017. pii: 10.1212/WNL.0000000000004524. doi: 10.1212/WNL.0000000000004524. |
| 526. | 16.2.31 | Bak S, Sindrup SH, Alslev T, Kristensen O, Christensen K, Gaist D. Cessation of smoking after first-ever stroke. Stroke 2002; 33: 2263-2269 |
| | | 16.3 Хроническая болезнь почек |
| 527. | 16.3.1 | Roger VL, Go AS, Lloyd-Jones DM et al. Heart Disease and Stroke Statistics 2012 Update: A Report From the American Heart Association. Circulation 2012; 125: 2-220. |
| 528. | 16.3.2 | Шальнова СА, Деев АД. Тенденции смертности в России в начале XXI века (по данным официальной статистики). Кардиоваскулярная терапия и профилактика 2011; 10(6): 5-10. |
| 529. | 16.3.3 | Kerr M, Bray B, Medcalf J, et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant 2012; 27(3): 73-80. |
| 530. | 16.3.4 | Coresh J, Stevens L, Levey A. Chronic kidney disease is common: What do we do next? Nephrol Dial Transplant 2008; 23(8): 1122-1125. |
| 531. | 16.3.5 | Xu R, Zhang L, Zhang P, et al. Comparison of the prevalence of chronic kidney disease among different ethnicities: Beijing CKD survey and American NHANES. Nephrol Dial Transplant 2009;24(4): 1220-6. |
| 532. | 16.3.6 | McClellan WM, Resnick B, Lei L, et al. Prevalence and Severity of Chronic |
| | | Kidney Disease and Anemia in the Nursing Home Population. J Am Med Dir Assoc 2010; 11: 33-41. |
| 533. | 16.3.7 | Amann K, Wanner C, Ritz E. Cross-Talk between the kidney and the cardiovascular system. J Am Soc Nephrol 2006; 17; 2112-2119. |
| 534. | 16.3.8 | Zoccali C, Goldsmith D, Agarwal R et al. The complexity of the cardio–renal link: taxonomy, syndromes, and diseases. Kidney Intern Suppl 2011; 1: 2-5. |
| 535. | 16.3.9 | Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008; 8: 117. |
| 536. | 16.3.10 | Zoccali C, Kramer A, Jager KJ. Epidemiology of CKD in Europe: an uncertain scenario. Nephrol Dial Transplant 2010; 25: 1731-1733. |
| 537. | 16.3.11 | Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97. |
| 538. | 16.3.12 | Henry RM, Kostense PJ, Bos G, et al. Mild renal insuffi ciency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62: 1402-1407. |
| 539. | 16.3.13 | Schillaci G, Reboldi G, Verdecchia P. Highnormal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 2001; 161: 886-891. |
| 540. | 16.3.14 | Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insuffi ciency. Kidney Int 1999; 56: 2214-2219. |
| 541. | 16.3.15 | Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305. |
| 542. | 16.3.16 | Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002;13(5): 1338-1349. |
| 543. | 16.3.17 | Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: 112-119. |
| 544. | 16.3.18 | Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295. |
| 545. | 16.3.19 | Herzog C. Kidney disease in cardiology. Nephrol Dial Transplant 2008; 23(8): 42-46. |
| 546. | 16.3.20 | Segura J, Garcia-Donair J, Praga M, et al. Chronic kidney disease as a situation of high added risk in hypertensive patients. J Am Soc Nephrol 2006; 17(2): 136-140. |
| 547. | 16.3.21 | Matsushita K, van der Velde M, Astor BC, et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375(9731): 2073-2081. |
| 548. | 16.3.22 | Gansevoort RT, Matsushita K, van der Velde M, et al. Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes: a collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80(1): 93-104. |
| 549. | 16.3.23 | Latchamsetty R, Fang J, Kline-Rogers E, et al. Prognostic Value of Transient and Sustained Increase in In-Hospital Creatinine on Outcomes of Patients Admitted With Acute Coronary Syndrome. Am J Cardiol 2007; 99 (7): 939- 42. |
| 550. | 16.3.24 | Ronco C, Bellomo R, McCullough PA. Cardiorenal syndromes in critical care. Contrib Nephrol 2010; 165: 366. |
| 551. | 16.3.25 | Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int 2012; 81: 819-25. |
| 552. | 16.3.26 | Piccinni P, Cruz DN, Gramaticopolo S, et al. Prospective multicenter study on epidemiology of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFROINT)/NEFROINT investigators. Minerva Anestesiol 2011; 77: 1072–83. |
| 553. | 16.3.27 | Kolhe NV, Muirhead AW, Wilkes SR, et al. National trends in acute kidney injury requiring dialysis in England between 1998 and 2013. Kidney Int 2015; 29. doi: 10.1038/ki.2015.234. |
| 554. | 16.3.28 | 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal doi:10.1093/eurheartj/ehw106 |
| 555. | 16.3.29 | van der Velde M, Matsushita K, Coresh J, et al. Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79(12): 1341-52 |
| 556. | 16.3.30 | Рабочая группа членов правления Научного общества нефрологов России. Национальные рекомендации. Хроническая болезнь почек: основные положения, определение, диагностика, скрининг, подходы к профилактике и лечению 2011. http://journal.nephrolog.ru/ckd/ |
| 557. | 16.3.31 | Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int (Suppl) 2013; 3: 1-150. |
| 558. | 16.3.32 | 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219. |
| 559. | 16.3.33 | Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int (Suppl) 2013; 3: 259-305. |
| 560. | 16.3.34 | Национальные рекомендации. Острое повреждение почек: основные принципы диагностики, профилактики и терапии. Ассоциация Нефрологов России. Научное общество нефрологов России, Москва 2014. nonr.ru/?page_id=3115 |
| 561. | 16.3.35 | Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int, (Suppl) 2012; 2: 1-138. |
| 562. | 16.3.36 | Clark H, Krum H, Hopper I. Worsening renal function during renin- angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction.Eur J Heart |
| | | Fail 2014; 16: 41-48. |
| | | 16.4 Перефирический атеросклероз |
| 563. | 16.4.1 | Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Röther J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO). The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS).Eur Heart J 2017. doi: 10.1093/eurheartj/ehx095. Epub ahead of print |
| 564. | 16.4.2 | de Weerd M, Greving JP, de Jong AW, Buskens E, Bots ML. Prevalence of asymptomatic carotid artery stenosis according to age and sex: systematic review and metaregression analysis. Stroke 2009; 40: 1105– 13. |
| 565. | 16.4.3 | Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382: 1329– 40. |
| 566. | 16.4.4 | Shadman R, Criqui MH, Bundens WP, Fronek A, Denenberg JO,Gamst AC, McDermott MM. Subclavian artery stenosis: prevalence, risk factors, and association with cardiovascular diseases. J Am Coll Cardiol 2004; 44: 618– 23. |
| 567. | 16.4.5 | Giannopoulos A, Kakkos S, Abbott A, Naylor AR, Richards T, Mikhailidis DP, Geroulakos G, Nicolaides AN. Long-term mortality in patients with asymptomatic carotid stenosis: implications for statin therapy. Eur J Vasc Endovasc Surg 2015; 50: 573–582. |
| 568. | 16.4.6 | Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015; 116: 1509–1526. |
| 569. | 16.4.7 | Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G, Wautrecht JC, Kornitzer M, Newman AB, Cushman M, Sutton-Tyrrell K, Fowkes FG, Lee AJ, Price JF, d’Agostino RB, Murabito JM, Norman PE, Jamrozik K, Curb JD, Masaki KH, Rodriguez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels G, Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi JD, Knottnerus JA, Ogren M, Hedblad B, Witteman JC, Breteler MM, Hunink MG, Hofman A, Criqui MH, Langer RD, Fronek A, Hiatt WR, Hamman R, Resnick HE, Guralnik J, McDermott MM. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008; 300: 197–208. |
| 570. | 16.4.8 | American Diabetes Association. Standards of medical care in diabetes- 2015 abridged for primary care providers. Clin Diabetes 2015 ; 33 (2):97- 11 |
| 571. | 16.4.9 | Приказ Министерства здравоохранения и социального развития |
| | | Российской Федерации № 597н от 19 августа 2009 года «Об организации деятельности центров здоровья по формированию здорового образа жизни у граждан Российской Федерации, включая сокращение потребления алкоголя и табака». http://www.minzdravsoc.ru/docs/mzsr/orders/930 |
| 572. | 16.4.10 | Lijmer JG, Hunink MG, van den Dungen JJ, Loonstra J, Smit AJ. ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Biol 1996; 22:3 91–398. |
| 573. | 16.4.11 | Stoffers HE, Kester AD, Kaiser V, Rinkens PE, Kitslaar PJ, Knottnerus JA. The diagnostic value of the measurement of the ankle-brachial systolic pressure index in primary health care. J Clin Epidemiol 1996; 49: 1401– 1405. |
| 574. | 16.4.12 | Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153. |
| 575. | 16.4.13 | ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–1559. |
| 576. | 16.4.14 | Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev 2013; 12:CD003075. |
| 577. | 16.4.15 | Antithrombotic Trialists’ Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860. |
| 578. | 16.4.16 | Lane R, Ellis B,Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev 2014;7:CD000990. |
| 579. | 16.4.17 | Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ, Ruckley CV. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992; 135: 331– 340. |
| 580. | 16.4.18 | Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769-1776. |
| 581. | 16.4.19 | Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A, Hosgood HD 3rd, Hoy D, Hu H, |
| | | Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khatibzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcenes W, March L, Marks R, Martin R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman TR, Micha R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, Orchard J, Osborne R, Ostro B, Page A, Pandey KD, Parry CD, Passmore E, Patra J, Pearce N, Pelizzari PM, Petzold M, Phillips MR, Pope D, Pope CA 3rd, Powles J, Rao M, Razavi H, Rehfuess EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, Rodriguez-Portales JA, Romieu I, Room R, Rosenfeld LC, Roy A, Rushton L, Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sapkota A, Seedat S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, Stapelberg NJ, Steenland K, Stockl H, Stovner LJ, Straif K, Straney L, Thurston GD, Tran JH, Van Dingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf AD, Yip P, Zielinski JM, Lopez AD, Murray CJ, Ezzati M, AlMazroa MA, Memish ZA. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-2260. |
| 582. | 16.4.20 | Malgor RD, Alahdab F, Elraiyah TA, Rizvi AZ, Lane MA, Prokop LJ, Phung OJ, Farah W, Montori VM, Conte MS, Murad MH. A systematic review of treatment of intermittent claudication in the lower extremities. J Vasc Surg 2015; 61(3): 54–73. |
| 583. | 16.4.21 | Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45: 645–654. |
| 584. | 16.4.22 | McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, Taylor L, Chan C, Sharma L, Schneider JR, Ridker PM, Green D, Quann M. Statin use and leg functioning in patients with and without lower- extremity peripheral arterial disease. Circulation 2003; 107: 757–761. |
| | | 16.5 ХСН |
| 585. | 16.5.1 | Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: the Task Force for the Diagnosis and Ttreatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129–200. DOI:10.1093/eurheartj/ehw128 |
| 586. | 16.5.2 | Мареев ВЮ, Фомин ИВ, Агеев ФТ, Арутюнов ГП, Беграмбекова ЮЛ, Беленков ЮН, Васюк ЮА, Галявич АС, Гарганеева АА, Гендлин ГЕ, Гиляревский СР, Глезер МГ, Драпкина ОМ, Дупляков ДВ, Кобалава ЖД, Козиолова НА, Лопатин ЮМ, Мареев ЮВ, Моисеев ВС, Недошивин АО и соавт. Хроническая сердечная недостаточность (ХСН). Журнал |
| | | Сердечная Недостаточность 2017; 18(1): 3-40. |
| 587. | 16.5.3 | Фомин ИВ. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал 2016; (8): 7–13. DOI:10.15829/1560-4071- 2016-8-7-13. |
| 588. | 16.5.4 | Терещенко СН, Жиров ИВ. Хроническая сердечная недостаточность. Руководство по кардиологии. Под ред. Чазова ЕИ. М., Практика 2014; 4: 192-291. |
| 589. | 16.5.5 | Latib А, Giannini А. Cardiac Interventions Today - The Next Frontier of Percutaneous Tricuspid Valve Repair. Cardiac Interventions Today 2016; 10(4): 54–9. |
| 590. | 16.5.6 | Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Eng J Med 2016; 375(13): 12 21–30. DOI:10.1056/NEJMoa1608029. |
| 591. | 16.5.7 | Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with chronic heart failure delays ventilatory anaerobic threshold and improves submaximal exercise performance. Circulation 1989; 79(2): 324–9. DOI:10.1161/01.CIR.79.2.324. |
| 592. | 16.5.8 | Smart N, Marwick TH. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. Am J Med 2004; 116(10): 693–706. DOI:10.1016/j.amjmed.2003.11.033 |
| 593. | 16.5.9 | Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004; 328(7433): 189–0. DOI:10.1136/bmj.37938.645220.EE |
| 594. | 16.5.10 | Isnard R, Pousset F, Trochu J-N, Chafirovska a O, Carayon A, Golmard JL, et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Card 2000; 86(4): 417–21. DOI:10.1016/S0002-9149(00)00957-7 |
| 595. | 16.5.11 | Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, et al. Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations. Circulation 2012; 126(18): 2261-74. DOI:10.1161/CIR.0b013e31826fb946 |
| 596. | 16.5.12 | Savard LA, Thompson DR, Clark AM. A meta-review of evidence on heart failure disease management programs: the challenges of describing and synthesizing evidence on complex interventions. Trials 2011; 12(1). DOI:10.1186/1745-6215 12-194 |
| 597. | 16.5.13 | Мареев ВЮ, Беграмбекова ЮЛ, Даниелян МО, Агеев ФТ, Гиляревский СР, Беленков ЮН и соавт. Какие вопросы задаются и на какие вопросы способны ответить исследования по немедикаментозному лечению пациентов с сердечной недостаточностью. Уроки исследования ШАНС. Журнал Сердечная Недостаточность 2014; 15(6): 383–96. |
| 598. | 16.5.14 | McDonald K, Ledwidge M, Cahill J, Quigley P, Maurer B, Travers B, et al. Heart failure management: Multidisciplinary care has intrinsic benefit above the optimization of medical care. J Cardiac Failure 2002; 8(3): 142– 8. DOI:10.1054/jcaf.2002.124340 |
| | | 16.6 Эректильная дисфункция |
| 599. | 16.6.1 | Vlachopoulos C, Jackson G, Stefanadis C, Montorsi P. Erectile dysfunction |
| | | in the cardiovascular patient. Eur Heart J 2013; 34: 2034–2046. |
| 600. | 16.6.2 | Montorsi P, Ravagnani PM, Galli S, Salonia A, Briganti A,Werba JP, Montorsi F. Association between erectile dysfunction and coronary artery disease: matching the right target with the right test in the right patient. Eur Urol 2006; 50: 721–731. |
| 601. | 16.6.3 | Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 2013; 6: 99–109. |
| 602. | 16.6.4 | Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 2011; 58: 1378–1385. |
| 603. | 16.6.5 | Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). European Heart Journal 2016;37(29):2315-2381. |
| 604. | 16.6.6 | Пушкарь ДЮ, Камалов АА, АльШукри СХ, Еркович АА, Коган МИ, Павлов ВН, Журавлев ВН, Берников АН. Эпидемиологическое исследование распространенности эректильной дисфункции в Российской Федерации. РМЖ 2012; 20; 3: 112-115. |
| 605. | 16.6.7 | Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2011; 171: 1797–1803. |
| 606. | 16.6.8 | Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): 2159-2219. |
| 607. | 16.6.9 | Manolis A, Doumas M. Sexual dysfunction: the «prima ballerina» of hypertension related quality-of-life complications. J Hypertens 2008; 26: 2074–2084. |
| 608. | 16.6.10 | Giagulli VA, Moghetti P, Kaufman JM, Guastamacchia E, Iacoviello M, Triggiani V. Managing erectile dysfunction in heart failure. Endocr Metab Immune Disord Drug Targets 2013; 13: 125-134. |
| 609. | 16.6.11 | Ponikowsky P, Voors AA, Anker SDб et al. 2016 ESC Guidelines for diagnosis and treatment of acute and chronic heart failure. The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(28): 2129-2200. |
| | | 16.7 Апное сна |
| 610. | 16.7.1 | Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on |
| | | Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-81. |
| 611. | 16.7.2 | Бабак СЛ, Горбунова МВ. Синдром обструктивного апноэ сна в клинической практике терапевта. Доктор.Ру 2014; 2(90): 63-71. |
| 612. | 16.7.3 | Gonzaga C, Bertolami A, Bertolami M, Amodeo C, Calhoun D. Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens 2015; 29: 705–712. |
| 613. | 16.7.4 | Konecny T, Kara T, Somers VK. Obstructive Sleep Apnea and Hypertension. Hypertension 2014; 63:203-209. |
| 614. | 16.7.5 | Ahmadi N, Chung SA, Gibbs A, Shapiro CM. The Berlin questionnaire for sleep apnea in a sleep clinic population: relationship to polysomnographic measurement of respiratory disturbance. Sleep Breath 2008; 12: 39–45. |
| 615. | 16.7.6 | JohnsMW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14: 540–545. |
| 616. | 16.7.7 | Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118: 1080–1111. |
| 617. | 16.7.8 | Martínez-García MA, Capote F, Campos-Rodríguez F, Lloberes P, Díaz de Atauri MJ, Somoza M, Masa JF, González M, Sacristán L, Barbé F, Durán- Cantolla J, Aizpuru F, Mañas E, Barreiro B, Mosteiro M, Cebrián JJ, de la Peña M, García-Río F, Maimó A, Zapater J, Hernández C, Grau SanMarti N, Montserrat JM; Spanish Sleep Network.Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA 2013; 310(22): 2407-15. doi: 10.1001/jama.2013.281250. |
| 618. | 16.7.9 | McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R, Drager LF, Liu Z, Chen G, Du B, McArdle N, Mukherjee S, Tripathi M, Billot L, Li Q, Lorenzi-Filho G, Barbe F, Redline S, Wang J, Arima H, Neal B, White DP, Grunstein RR, Zhong N, Anderson CS; SAVE Investigators and Coordinators. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. N Engl J Med 2016 8; 375(10): 919-31. |
| 619. | 16.7.10 | Yu J, Zhou Z, McEvoy RD, Anderson CS, Rodgers A, Perkovic V, Neal B. Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep ApneaA Systematic Review and Meta-analysis. JAMA 2017; 318(2): 156–166. doi:10.1001/jama.2017.7967. |
| | | 16.8 Кардиоваскулярная профилактика при онкологических заболеваниях |
| 620. | 16.8.1 | Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzo M, Esteve J. Enalapril and carvedilol for |
| | | preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013; 61: 2355-2362. |
| 621. | 16.8.2 | Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 2013; 49: 2900-2909. |
| 622. | 16.8.3 | Darby S, McGale P, Peto R, Granath F, Hall P, Ekbom A. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women. BMJ 2003; 326: 256-257. |
| 623. | 16.8.4 | Smith GL, Smith BD, Buchholz TA, Giordano SH, Garden AS, Woodward WA, Krumholz HM, Weber RS, Ang KK, Rosenthal DI. Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol 2008;26: 5119-5125. |
| 624. | 16.8.5 | Fajardo LF. Is the pathology of radiation injury different in small vs large blood vessels? Cardiovasc Radiat Med 1999; 1: 108-110. |
| 625. | 16.8.6 | van der Pal HJ, van Dalen EC, van Delden E, van Dijk IW, Kok WE, Geskus RB, Sieswerda E, Oldenburger F, Koning CC, van Leeuwen FE, Caron HN, Kremer LC. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012; 30: 1429-1437. |
| 626. | 16.8.7 | Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, TaylorCW, van Leeuwen FE. Long-term risk of cardiovascular disease in 10- year survivors of breast cancer. J Natl Cancer Instit 2007; 99: 365–375. |
| 627. | 16.8.8 | Yeh JM, Nohria A, Diller L. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med 2014; 160: 661–671. |
| 628. | 16.8.9 | Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncology 2002; 13: 699–709. |
| 629. | 16.8.10 | Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 987–998. |
| 630. | 16.8.11 | Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev 2012; 8: CD008465. |
| 631. | 16.8.12 | McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European |
| | | Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–1847. |
| 632. | 16.8.13 | Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014; 15: 1063– 1093. |
| 633. | 16.8.14 | Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncology 2012; 23(Suppl 7): 155–166. |
| 634. | 16.8.15 | Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55: 213–220. |
| 635. | 16.8.16 | Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077–1084. |
| | | 16.9 Аутоиммуные заболевания |
| 636. | 16.9.1 | Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325–331. |
| 637. | 16.9.2 | Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957–63 |
| 638. | 16.9.3 | Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P. Predicting cardiovascular risk in England andWales: prospective derivation and validation of QRISK2. BMJ 2008; 336: 1475–1482. |
| 639. | 16.9.4 | Попкова ТВ, Новикова ДС, Насонов ЕЛ. Рекомендации по снижению кардиоваскулярного риска у пациентов с воспалительными артритами (по материалам рекомендаций европейской антиревматической лиги) Современная ревматология 2010; 1: 7-11. |
| 640. | 16.9.5 | Crowson CS, Gabriel SE. Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. Ann Rheum Dis 2011;70(5): 719-21. |
| 641. | 16.9.6 | Новикова ДС, Попкова ТВ, Насонов ЕЛ. Современные представления о патогенезе и особенности лечения артериальной гипертензии у больных ревматоидным артритом. Терапевтический архив; 5: 24-33. |
| 642. | 16.9.7 | Ревматология: Клинические рекомендации. Под редакцией Е.Л. Насонова. М.:ГЭОТАР-Медиа, 2010. |
| 643. | 16.9.8 | Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). European Heart Journal 2016; 37(29):2315-2381. |
| 644. | 16.9.9 | Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012; 64: 2836–2846. |
| 645. | 16.9.10 | Edwards CJ, Rheumatism 2009; 58 (9): 420. |
| 646. | 16.9.11 | De Vera MA, Choi H, Abrahamowicz M, Kopec J, Goycochea-Robles MV, Lacaille D.Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2011;70(6): 1020-4. |
| 647. | 16.9.12 | Sheng X, Murphy MJ, Macdonald TM, Wei L. The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population. BMC Public Health 2012; 12(1): 712. |
| 648. | 16.9.13 | Kremers HM, Nicola PJ, Crowson CS. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis & rheumatism 2004; 11: 3450 – 3457. |
| 649. | 16.9.14 | Ajeganova S, Andersson ML, Hafström I; for the BARFOT study group. Obesity is associated with worse disease severity in rheumatoid arthritis as well as with co-morbidities - a longterm follow-up from disease onset. Arthritis Care Res 2012 doi:10.1002/acr.21710. |
| 650. | 16.9.15 | Board JBS. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014; 100(Suppl 2): 1– 67. |
| 651. | 16.9.16 | Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, Troxel AB, Hennessy S, Kimmel SE, Margolis DJ, Choi H, Mehta NN, Gelfand JM. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2015; 74: 326–332. |
| 652. | 16.9.17 | Ahlehoff O, Gislason GH, Jorgensen CH. Psoriasis and risk of atrial fibrillation and ischemic stroke: Danish Nationalwide Cohort Study. EurHeart J 2011; 33(16): 2054-2064. |
| | | 16.10 Периодонтит |
| 653. | 16.10.1 | Jimenez M, Krall EA, Garcia RI, Vokonas PS, Dietrich T. Periodontitis and incidence of cerebrovascular disease in men. Ann Neurol 2009; 66: 505- 512. |
| 654. | 16.10.2 | Dietrich T, Jimenez M, Krall Kaye EA, Vokonas PS, Garcia RI. Age- dependent associations between chronic periodontitis/edentulism and risk of coronary heart disease. Circulation 2008;117:1668-1674. |
| 655. | 16.10.3 | Beck JD, Eke P, Lin D, Madianos P, Couper D, Moss K, Elter J, Heiss G, Offenbacher S. Associations between IgG antibody to oral organisms and |
| | | carotid intima-medial thickness in community-dwelling adults. Atherosclerosis 2005;183: 342-348. |
| 656. | 16.10.4 | Desvarieux M, Demmer RT, Jacobs DR, Papapanou PN, Sacco RL, Rundek T. Changes in clinical and microbiological periodontal profiles relate to progression of carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology study. J Am Heart Assoc 2013;2:e000254. |
| 657. | 16.10.5 | Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Volzke H, Tuomainen TP, Sander D, Plichart M, Catapano AL, Robertson CM, Kiechl S, Rundek T, Desvarieux M, Lind L, Schmid C, DasMahapatra P, Gao L, Ziegelbauer K, Bots ML, Thompson SG. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012; 379: 2053-2062. |
| | | 17.1 Особенности кардиоваскулярной профилактики у детей и подростков |
| 658. | 17.1.1 | Кучма ВР. Основы формирования здоровья детей. Учебное пособие. Феникс 2016. |
| 659. | 17.1.2 | Kavey REW, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J. Cardiovascular Risk Reduction in High-Risk Pediatric Patients. A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. Endorsed by the American Academy of Pediatrics. Circulation 2006;114: 2710-2738. |
| 660. | 17.1.3 | Погосова НВ, Вергазова ЭК, Аушева АК, Юсубова АИ, Исакова СС, Бойцов СА. Актуальные результаты работы центров здоровья России. Профилактическая медицина 2016; 6: 50-58. doi: 10.17116/profmed201619550-58. |
| 661. | 17.1.4 | Погосова НВ, Кучма ВР, Юферева ЮМ, Аушева АК, Горелова ЖД, Седова АС, Храмцов ПИ, Звездина ИВ, Кутушев ОТ, Киселева АВ, Петряйкина ЕЕ, Кузьмина ЭМ, Полярус МА. Оказание медицинской помощи детскому населению в центрах здоровья для детей. Методические рекомендации. Москва 2017. |
| 662. | 17.1.5 | Тутульян ВА и соавт. Распространенность ожирения и избыточной массы тела среди детского населения РФ: мультицентровое исследование. Педиатрия 2015; 93(5): 28. |
| 663. | 17.1.6 | Varvarigou AA. Intrauterine growth restriction as a potential risk factor for disease onset in adulthood. J Pediatr Endocrinol Metab 2010; 23(3): 215- 24. |
| 664. | 17.1.7 | Журавлёва ИВ. Здоровье подростков: социологический анализ. Москва. Институт социологии РАН. 2002.240с. |
| 665. | 17.1.8 | GATS глобальный опрос взрослого населения о потреблении табака. Российская Федерация 2009, страновой отчет. http://www.who.int/tobacco/surveillance/ru_tfi_gatsrussian_countryrepo rt.pdf |
| 666. | 17.1.9 | ВОЗ Европейское Региональное бюро. Неравенства в период взросления: гендерные и социально-экономические различия в показателях здоровья и благополучия детей и подростков. Исследование "Поведение детей школьного возраста в отношении здоровья" (HBSC): международный отчет по результатам исследования 2013/2014 гг. Копенгаген, Дания 2016. http://www.euro.who.int/ data/assets/pdf_file/0016/331711/HSBC- No.7-Growing-up-unequal-Full-Report-ru.pdf?ua=1 |
| 667. | 17.1.10 | Национальные рекомендации по профилактике сердечно-сосудистых заболеваний в детском и подростковом возрасте. Российский кардиологический журнал 2012 6 (98), приложение 1. |
| 668. | 17.1.11 | Report of commission on ending childhood obesity. World Health Organization 2016. |
| 669. | 17.1.12 | Lurbe E, Agabiti-Rosei E, Cruickshank JKб et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. Journal of Hypertension 2016, 34: 1887-1920 DOI:10.1097/HJH.0000000000001039 |
| 670. | 17.1.13 | Daniels SR, Greer FR and the Committee on Nutrition. Lipid Screening and Cardiovascular Health in Childhood. Pediatrics 2008; 122;198-208 |
| 671. | 17.1.14 | Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: Association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics 2005; 115(3): 290-296. |
| 672. | 17.1.15 | Whitaker RC. Predicting preschooler obesity at birth: the role of maternal obesity in early pregnancy. Pediatrics 2004; 114(1): 29-36. |
| 673. | 17.1.16 | Глобальная стратегия по кормлению детей грудного и раннего возраста. ВОЗ ЮНИСЕФ. 2003. http://www.who.int/publications/list/9241562218/ru/. |
| 674. | 17.1.17 | Barker DJ, Osmond C, Forsen TJ, Kajantie E, Eriksson JG.Trajectories of growth among children who have coronary events as adults. N Engl J Med 2005; 353:(17): 1802-1809. |
| 675. | 17.1.18 | Rich-Edwards JW, Kleinman K, Michels KB, Stampfer MJ, Manson JE, Rexrode KM, Hibert EN, Willett WC. Longitudinal study of birth weight and adult body mass index in predicting risk of coronary heart disease and stroke in women. BMJ 2005; 330(7500): 1115. |
| 676. | 17.1.19 | Kavey R-E.W. , Daniels S.R., Lauer R.M. , Atkins D.L. , Hayman L.L., Taubert K. American Heart Association Guidelines for Primary Prevention of Atherosclerotic Cardiovascular Disease Beginning in Childhood. Circulation 2003; 107; 1562-1566 |
| 677. | 17.1.20 | Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Full Report 2012 |
| 678. | 17.1.21 | Глобальные рекомендации по физической активности для здоровья. ВОЗ 2010. |
| 679. | 17.1.22 | Goldstein BI, Carnethon MR, Matthews KA, et al. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease. Circulation 2015. DOI: 10.1161/CIR.0000000000000229. |
| | | 17.2 Особенности профилактики ССЗ у лиц пожилого и старческого возраста |
| 680. | 17.2.1 | Ткачева ОН, Рунихина НК, Котовская ЮВ, Шарашкина НВ, Остапенко ВС. Лечение артериальной гипертонии у пациентов 80 лет и старше и пациентов со старческой астенией Согласованное мнение экспертов Российской ассоциации геронтологов и гериатров, Геронтологического общества при Российской академии наук, Российского медицинского общества по артериальной гипертонии. Кардиоваскулярная терапия и профилактика 2017; 16(1). |
| 681. | 17.2.2 | Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219. |
| 682. | 17.2.3 | Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). European Heart Journal 2016; 37(29): 2315-2381. |
| 683. | 17.2.4 | Дедов ИИ, Шестакова МВ, Майоров АЮ. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (клинические рекомендации,8-й выпуск.). Сахарный диабет 2017; 20(1): 1-112. DOI: 10.14341/DM20171S8. |
| 684. | 17.2.5 | Kutner JS, Blatchford PJ, Taylor DH Jr, Ritchie CS, Bull JH, Fairclough DL, Hanson LC, LeBlanc TW, Samsa GP, Wolf S, Aziz NM, Currow DC, Ferrell B, Wagner-Johnston N, Zafar SY, Cleary JF, Dev S, Goode PS, Kamal AH, Kassner C, Kvale EA, McCallum JG, Ogunseitan AB, Pantilat SZ, Portenoy RK, Prince-Paul M, Sloan JA, Swetz KM, Von Gunten CF, Abernethy AP. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med 2015; 175: 691-700. |
| 685. | 17.2.6 | Flicker L, McCaul KA, Hankey GJ, Jamrozik K, Brown WJ, Byles JE, Almeida OP. Body Mass Index and Survival in Men and Women Aged 70 to 75. Journal of the American Geriatrics Society 2010; 58: 234-241. doi:10.1111/j.1532-5415.2009.02677.x. |
| | | 17.3 Особенности профилактики ССЗ у женщин |
| 686. | 17.3.1 | Демографический ежегодник России 2015: Стат. сб.Росстат. – M., 2015: 263с. |
| 687. | 17.3.2 | Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update: A Guideline From the American Heart Association. Circulation 2011; 123(11): 1243-1262. |
| 688. | 17.3.3 | Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by |
| | | representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-81. |
| 689. | 17.3.4 | Муромцева ГА, Концевая АВ, Константинов ВВ, Артамонова ГВ, Гатагонова ТМ, Дупляков ДВ, Ефанов АЮ, Жернакова ЮВ, Ильин ВА, Конради АО, Либис РА, Минаков АВ, Недогода СВ, Ощепкова ЕВ, Романчук СА, Ротарь ОП, Трубачева ИА, Деев АД, Шальнова СА, Чазова ИЕ, Шляхто ЕВ, Бойцов СА. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика 2014; 13(6): 4–11. |
| 690. | 17.3.5 | Pogosova N, Saner H, Pedersen SS, Cupples ME, McGee H, Hofer S, Doyle F, Schmid JP, von Kanel R. Psychosocial aspects in cardiac rehabilitation: from theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol 2015; 22: 1290–1306. |
| 691. | 17.3.6 | Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health (Larchmt) 2014; 23(2): 112-119. doi: 10.1089/jwh.2012.3972. Epub 2013 Nov. |
| 692. | 17.3.7 | Shrank WH, Liberman JN, Fischer MA, Kilabuk E, Girdish C, Cutrona S, Brennan T, Choudhry NK. Are caregivers adherent to their own medications? JAmPharmAssoc (2003) 2011; 51(4):492-498. |
| 693. | 17.3.8 | Погосова НВ, Оганов РГ, Бойцов СА, Аушева АК, Соколова ОЮ, Курсаков АА, Поздняков ЮМ, Салбиева АО, Юсубова АИ, Лельчук ИН, Гусарова ТА, Гомыранова НВ, Сказин НА, Елисеева НА, Ахмедова ЭБ, Бедейникова КК, Ковригина МН. Медикаментозная терапия у пациентов с ишемической болезнью сердца в России и Европе: результаты российской части международного многоцентрового исследования EUROASPIRE IV. Кардиология 2016; 12: 5-11. |
| 694. | 17.3.9 | Погосова НВ, Соколова ОЮ, Юферева ЮМ, Осипова ИВ, Рямзина ИН от имени группы исследователей российской части исследования EuroCaRe-D. Первые результаты анализа российской части европейского регистра по кардиореабилитации (European Cardiac Rehabilitation Database – EuroCaReD) с участием 13 стран. Кардиология 2015; 55 (2): 49-56. |
| 695. | 17.3.10 | Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009; 53: 944–51. |
| 696. | 17.3.11 | Skjaerven R, Wilcox AJ, Klungsoyr K, Irgens LM, Vikse BE, Vatten LJ, Lie RT. Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study. BMJ 2012; 345: e7677. |
| 697. | 17.3.12 | Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, Smith WC. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003; |
| | | 326: 845. |
| 698. | 17.3.13 | Engeland A, Bjorge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, Furu K. Risk of diabetes after gestational diabetes and preeclampsia. A registry- based study of 230,000 women in Norway. Eur J Epidemiol 2011; 26:157- 163. |
| 699. | 17.3.14 | Lykke JA, Paidas MJ, Damm P, Triche EW, Kuczynski E, Langhoff-Roos J. Preterm delivery and risk of subsequent cardiovascular morbidity and type-II diabetes in the mother. BJOG 2010; 117: 274-281. |
| 700. | 17.3.15 | Marin R, Gorostidi M, Portal CG, Sanchez M, Sanchez E, Alvarez J. Long- term prognosis of hypertension in pregnancy. Hypertens Pregnancy 2000;19:199–209. |
| 701. | 17.3.16 | Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009; 373: 1773-1779. |
| 702. | 17.3.17 | Venkataraman H, Sattar N, Saravanan P. Postnatal testing following gestational diabetes: time to replace the oral glucose tolerance test? Lancet Diabetes Endocrinol 2015; 3: 754-756. |
| 703. | 17.3.18 | Hastie CE, Smith GC, Mackay DF, Pell JP. Maternal risk of ischaemic heart disease following elective and spontaneous pre-term delivery: retrospective cohort study of 750 350 singleton pregnancies. Int J Epidemiol 2011; 40(4): 914-919. |
| 704. | 17.3.19 | Heida KY, Velthuis BK, Oudijk MA, Reitsma JB, Bots ML, Franx A, vanDunné FM; Dutch Guideline Development Group on Cardiovascular Risk Management after Reproductive Disorders. Cardiovascular disease risk in women with a history of spontaneous preterm delivery: A systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23(3): 253-263. |
| 705. | 17.3.20 | Parker DR, Lu B, Sands-Lincoln M, Kroenke CH, Lee CC, O'Sullivan M, Park HL, Parikh N, Schenken RS, Eaton CB. Risk of cardiovascular disease among postmenopausal women with prior pregnancy loss: the women's health initiative. Ann Fam Med 2014 ; 12(4): 302-309. |
| 706. | 17.3.21 | Bonamy AK, Parikh NI, Cnattingius S, Ludvigsson JF, Ingelsson E. Birth characteristics and subsequent risks of maternal cardiovascular disease: effects of gestational age and fetal growth. Circulation 2011; 124: 2839– 2846. |
| 707. | 17.3.22 | Sanghavi M, Kulinski J, Ayers CR, et al. Association between number of live births and markers of subclinical atherosclerosis: The Dallas Heart Study. European journal of preventive cardiology 2016; 23(4): 391-399. doi:10.1177/2047487315571891. |
| 708. | 17.3.23 | Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, RogersW, Pepine CJ. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93: 1276-1284. |
| 709. | 17.3.24 | Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus |
| | | matched, reference controls: a retrospective, observational study. J Clin Endocrinol Metab 2012; 97: 3251-3260. |
| 710. | 17.3.25 | Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16: 347– 363. |
| 711. | 17.3.26 | Hong JS, Yi SW, Kang HC, Jee SH, Kang HG, Bayasgalan G, Ohrr H. Age at menopause and cause-specific mortality in South Korean women: Kangwha Cohort Study. Maturitas 2007; 56: 411–419. |
| 712. | 17.3.27 | Canoy D, Beral V, Balkwill A, Wright FL, Kroll ME, Reeves GK, Green J, Cairns BJ; Million Women Study Collaborators. Age at menarche and risks of coronary heart and other vascular diseases in a large UK cohort. Circulation 2015; 131(3): 237-44. |
| 713. | 17.3.28 | Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288(3): 321–333. |
| 714. | 17.3.29 | Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 2012; 15(3): 217-28. |
| 715. | 17.3.30 | Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013; 310(13): 1353-68. |
| 716. | 17.3.31 | Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015; (3): CD002229. |
| 717. | 17.3.32 | Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016 ; 19(2): 109-50. |
| | | 18. Антитромбоцитарная |
| 718. | 18.1 | Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494– 502. |
| 719. | 18.2 | Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001- 2015. |
| 720. | 18.3 | Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, |
| | | Horrow J, Husted S, James S, Katus H, MahaffeyKW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057. |
| 721. | 18.4 | Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012; 60: 1340-1348. |
| 722. | 18.5 | Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmao M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013; 310: 2510-2522. |
| 723. | 18.6 | Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012; 125: 505-513. |
| 724. | 18.7 | Schulz-Schupke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tolg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Mudra H, von Hodenberg E, Wohrle J, Angiolillo DJ, von Merzljak B, Rifatov N, Kufner S, Morath T, Feuchtenberger A, Ibrahim T, Janssen PW, Valina C, Li Y, Desmet W, Abdel-Wahab M, Tiroch K, Hengstenberg C, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Schomig A, Mehilli J, Kastrati A. ISAR- SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015; 36: 1252-1263. |
| 725. | 18.8 | Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-2166. |
| 726. | 18.9 | Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791- 1800. |
| 727. | 18.10 | Antithrombotic Trialists’ Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: |
| | | 1849-1860. |
| 728. | 18.11 | De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2007; 3: CD001820. |
| 729. | 18.12 | Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-251. |
| 730. | 18.13 | Farrell B, Godwin J, Richards S,Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-1054. |
| 731. | 18.14 | Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-451. |
| 732. | 18.15 | Liu M, Counsell C, Sandercock P. Anticoagulants for preventing recurrence following ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev 2000; 2: CD000248. |
| 733. | 18.16 | Fuster V, Bhatt DL, Califf RM, Michelson AD, Sabatine MS, Angiolillo DJ, Bates ER, Cohen DJ, Coller BS, Furie B, Hulot JS, Mann KG, Mega JL, Musunuru K, O'Donnell CJ, Price MJ, Schneider DJ, Simon DI, Weitz JI, Williams MS, Hoots WK, Rosenberg YD, Hasan AA. Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation 2012; 126(13): 1645-62. |
| 734. | 18.17 | Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-81. |
| 735. | 18.18 | Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, Sugawara M, Ando K, Murata M, Yokoyama K, Ishizuka N. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014; 312: 2510–2520. |
| 736. | 18.19 | Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717. |
| 737. | 18.20 | De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, Valentini U, Nicolucci A. Aspirin and Simvastatin Combination for |
| | | Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007; 8: 21. |
| 738. | 18.21 | Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) Trial. http://www.arrivestudy.com. |
| 739. | 18.22 | Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71– 86. |
| 740. | 18.23 | CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin inpatients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339. |
| 741. | 18.24 | Udell JA, Bonaca MP, Collet J-P, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine M, Braunwald E, Bhatt DL. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J 2016; 37: 390-399. |
| 742. | 18.25 | Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19. |
| 743. | 18.26 | Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax J, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267—315 |
| 744. | 18.27 | Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head S J, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter D J, Schauerte P, Uva MS, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns Wi, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of theEuropeanAssociation of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-2619. |
| 745. | 18.28 | Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340: 1421-1425 |
| 746. | 18.29 | Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt A K, Hulot J-S, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, |
| | | Senior R, Taggart D P, van der Wall E E, Vrints CJM. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003 |
| 747. | 18.30 | Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators.Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377(14): 1319-1330. |
| 748. | 18.31 | Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, Xie JX, Warlow C, Peto R. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST collaborative groups. Stroke 2000; 31: 1240–1249 |
| 749. | 18.32 | Wang Y, Pan Y, Zhao X, Li H, Wang D, Johnston SC, Liu L, Meng X, Wang A, Wang C, Wang Y. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes. Circulation 2015; 132: 40–46 |
| 750. | 18.33 | Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo- controlled trial. Lancet 2004; 364: 331-337 |
| 751. | 18.34 | Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta- analysis of randomized trials. JAMA 2009; 301: 1909-1919 |
| 752. | 18.35 | Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, Cates CU, Creager MA, Fowler SB, Friday G, Hertzberg VS, McIff EB, Moore WS, Panagos PD, Riles TS, Rosenwasser RH, Taylor AJ. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SV S Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Developed in Collaboration With the American Academy of Neurology and Society of Cardiovascular Computed Tomography. Circulation 2011; 124: 489-532 |
| 753. | 18.36 | Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, |
| | | Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Röther J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS).Eur Heart J 2017. doi: 10.1093/eurheartj/ehx095. |
| 754. | 18.37 | Anand S et al. COMPASS PAD: Cardiovascular Outcomes for People Using Anticoagulation Strategies trial: Results in patients with peripheral artery disease. European Society of Cardiology 2017 Congress. August 27, 2017; Barcelona, Spain. |
| 755. | 18.38 | Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38): 2893-2962. |
| 756. | 18.39 | Vadmann H, Nielsen PB, Hjortshoj SP, Riahi S, Rasmussen LH, Lip GY, Larsen TB. Atrial flutter and thromboembolic risk: a systematic review. Heart 2015; 101: 1446-1455. |
| 757. | 18.40 | Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A, Diaz R, Hohnloser SH, Lewis BS, Shestakovska O,Wang J, Connolly SJ. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirintreated patients in ACTIVE-A and AVERROES. Eur Heart J 2015; 36: 281-287. |
| 758. | 18.41 | Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, Fauchier L. Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. Int J Cardiol 2013; 167: 2682-2687. |
| 759. | 18.42 | Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507 |
| 760. | 18.43 | Кардиоваскулярная профилактика. Национальные рекомендации. Разработаны Комитетом экспертов Всероссийского научного общества кардиологов и Национальным на¬учным обществом «Кардиоваскулярная терапия и профилактика». Кардиоваскулярная терапия и профилактика 2011; 10(6). |
| 761. | 18.44 | Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J, Gimeno JR, Sogorb F, Valdes M, Lip GYH. Anticoagulant and antiplatelet therapy |
| | | use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51: 818–825. |
| 762. | 18.45 | Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Muñoz DR, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL. 2017 ESC/EACTS Guidelines for the management of valvular heart disease: The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio- Thoracic Surgery (EACTS). Eur Heart J 2017. doi: 10.1093/eurheartj/ehx391. |
| 763. | 18.46 | Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635–641 |
| 764. | 18.47 | Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, Chow J, Ng RP, Tse TF. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985; 72: 1059–1063 |
| 765. | 18.48 | Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R, Bradford K, Tyndel S, Alonso-Coello P, Ansell J, Beyth R, Bernardo A, Christensen TD, Cromheecke ME, Edson RG, Fitzmaurice D, Gadisseur AP, Garcia-Alamino JM, Gardiner C, Hasenkam JM, Jacobson A, Kaatz S, Kamali F, Khan TI, Knight E, Kortke H, Levi M, Matchar D, Menendez-Jandula B, Rakovac I, Schaefer C, Siebenhofer A, Souto JC, Sunderji R, Gin K, Shalansky K, Voller H, Wagner O, Zittermann A. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012; 379: 322–334 |
| 766. | 18.49 | Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sarafoff N. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial. J Am Coll Cardiol 2015; 65: 1619–1629. |
| 767. | 18.50 | Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423–2434 |
| 768. | 18.51 | Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van‘t Hof AW, ten Berg, JM, WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107–1115 |
| 769. | 18.52 | Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP, Sorensen R, Kober L, Torp-Pedersen C, Hansen ML. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014; 129: 1577–1585 |
| 770. | 18.53 | Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F, RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369: 1206–1214 |
| 771. | 18.54 | Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH. Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 195–226 |
| 772. | 18.55 | Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs J SR, Huisman M, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Noordegraaf AV, Zamorano JL, Zompatori M. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur Heart J 2014; 35: 3033-3069 |
| 773. | 18.56 | Kearon C., Akl E.A., Ornelas J., Blaivas A., Jimenez D., Henri Bounameaux, Menno Huisman, Christopher S. King, Timothy A. Morris, Namita Sood, Scott M. Stevens, Janine R. E. Vintch, Philip Wells, Scott C. Woller, Lisa Moores. Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report. Chest 2016; 149: 315-352 |
| 774. | 18.57 | Бокерия ЛА, Затевахин ИИ, Кириенко АИ, Андрияшкин АВ, Андрияшкин ВВ, Арутюнов ГП, Баринов ВЕ, Бицадзе ВО, Бодыхов МК, Бритов АН, Бутенко АВ, Вавилова ТВ, Воробьёва НА, Восканян ЮЭ, Гавриленко АВ, Галстян ГМ, Гельфанд БР, Гиляров МЮ, Голубев ГШ, Замятин МН, Золотухин ИА, Кобалава ЖД, Кательницкий ИИ, Копёнкин СС, Кузнецов МР, Леонтьев СГ, Лобастов КВ, Лубнин АЮ, Макацария АД, Моисеев ВС, Момот АП, Острякова ЕВ, Панченко ЕП, Переходов СН, Пирадов МА, Поддубная ИВ, Покровский АВ, Проценко ДН, Прудков МИ, Прядко СИ, Пырегов АВ, Решетняк ТМ, Рябинкина ЮВ, Сапелкин СВ, Семёнова МН, Смирнов СВ, Соколов ВА, Стаховская ЛВ, Стойко ЮМ, Сулимов ВА, Сухих ГТ, Терещенко СН, Фокин АА, Хруслов МВ, Шевела АИ, Шиманко АИ, Шулутко АМ, Явелов ИС, Яхонтов ДИ. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология 2015; 9 (4): 3-52 |
| | | 19. Приверженность |
| 775. | 19.1 | Sabate E. Adherence to long-term therapies: evidence for action. WHO Geneva 2003. |
| 776. | 19.2 | Osterberg L, Blaschke T. Adherence to medication. N Engl JMed 2005; 353(5): 487-497. |
| 777. | 19.3 | McGinnis B, Olson KL, Magid D et al. Factors related to adherence to statin therapy. Ann Pharmacother 2007; 41(11): 1805-11. |
| 778. | 19.4 | Погосова ГВ, Колтунов ИЕ, Мелик-Оганджанян ГЮ, Соколова ОЮ. Приверженность лечению сердечно-сосудистых заболеваний: |
| | | проблема врачей и пациентов. Кардиоваскулярная терапия и профилактика 2009; 8(4): 98-102. |
| 779. | 19.5 | Banerjee A, Khandelwal S, Nambaiar L, et al. Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: a systematic review. Open Heart 2016; 2(3): e000438. |
| 780. | 19.6 | Maimaris W, Paty J, Perel P et al. The influence of health systems on hypertension awareness, treatment, and control: a systematic literature review. PLoS Med 2013; 10: e1001490 |
| 781. | 19.7 | Wang L. Physician-related barriers to hypertension management. Med Princ Pract 2004; 13(5): 282-5. |
| 782. | 19.8 | Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries:the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002; 19(6): 596-604. |
| 783. | 19.9 | Karbach U, Schubert I, Hagemeister J, Ernstmann N, Pfaff H, Höpp HW. Physician’s knowledge of and compliance with guidelines: an exploratory study in cardiovascular diseases. Dtsch Arztebl Int 2011; 108(5): 61-9. doi: 10.3238/arztebl.2011.0061. Epub 2011 Feb 4 |
| 784. | 19.10 | Kolandaivelu K, Leiden BB, O'Gara PT, Bhatt DL. Non-adherence to cardiovascular medication. Eur Heart J. 2014; 35(46): 3267-3276. doi: 10.1093/eurheartj/ehu364. Epub 2014 Sep 28. |
| 785. | 19.11 | Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013, 34: 2940-2948. |
| 786. | 19.12 | Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009; 119: 390–397. |
| 787. | 19.13 | Чазов ЕИ, Оганов РГ, Погосова ГВ, Деев АД, Шальнова СА, Колтунов ИЕ, Ромасенко ЛВ. Депрессивная симптоматика ухудшает прогноз у больных артериальной гипертонией и ишемической болезнью сердца: первые результаты проспективного этапа российского многоцентрового исследования КООРДИНАТА. Кардиология 2007; 10: 24-30. |
| 788. | 19.14 | Zhao S, Zhao H, Wang L, Du S, Qin Y. Education is ctitical for medication adherence in patients with coronary heart didease.Acta Cardiol 2015; 70(2): 197-204. |
| 789. | 19.15 | Zullig LL, Ramos K, Bosworth HB. Improving Medication adherence in coronary heart disease. Curr Cardiol Rep 2017 Sep 22; 19(11): 113. doi: 10.1007/s11886-017-0918-y. Review. |
| 790. | 19.16 | Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24(1): 67-74. |
| 791. | 19.17 | Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15. |
| 792. | 19.18 | Погосова ГВ, Белова ЮС, Рославцева АН. Приверженность к лечению |
| | | артериальной гипертонии и ишемической болезни сердца – ключевой элемент снижения сердечносо-судистой смертности Кардиоваскулярная терапия и профилактика 2007; 6(1). |
| 793. | 19.19 | Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119: 3028–3035. |
| 794. | 19.20 | Оганов РГ, Погосова ГВ, Колтунов ИЕ и соавт. РЕЛИФ – Регулярное Лечение И проФилактика – ключ к улучшению ситуации с сердечно- сосудистыми заболеваниями в России: результаты российского многоцентрового исследования. Часть I. Кардиология 2007; 47(5): 58- 66. |
| 795. | 19.21 | Оганов РГ, Погосова ГВ, Колтунов ИЕ и соавт. РЕЛИФ – Регулярное Лечение И проФилактика – ключ к улучшению ситуации с сердечно- сосудистыми заболеваниями в России: результаты российского многоцентрового исследования. Часть II. Кардиология 2007; 47(11): 30-9. |
| 796. | 19.22 | Оганов РГ, Погосова ГВ, Колтунов ИЕ и соавт. РЕЛИФ – Регулярное Лечение И проФилактика – ключ к улучшению ситуации с сердечно- сосудистыми заболеваниями в России: результаты российского многоцентрового исследования. Часть III. Кардиология 2008; 48(4): 46- 53. |
| 797. | 19.23 | Бойцов СА, Марцевич СЮ, Гинзбург МЛ, Кутишенко НП, Дроздова ЛЮ, Акимова АВ, Суворов АЮ, Лукьянов, ММ, Дмитриева НА, Лерман ОВ, Журавская НЮ, Даниэльс ЕВ, Фокина АВ, Юдаев ВН, Смирнов ВП, Калинина АМ, Котов СВ, Стаховская ЛВ. Люберецкое исследование смертности больных, перенесших мозговой инсульт или транзиторную ишемическую атаку (ЛИС-2). Дизайн и оценка лекарственной терапии. Рациональная фармакотерапия в кардиологии 2013; 9(2): 114-122. |
| 798. | 19.24 | Погосова НВ, Оганов РГ, Бойцов СА, Аушева АК, Соколова ОЮ, Курсаков АА, Поздняков ЮМ, Салбиева АО, Юсубова АИ, Лельчук ИН, Гусарова ТА, Гомыранова НВ, Сказин НА, Елисеева НА, Ахмедова ЭБ, Бедейникова КК, Ковригина МН. Медикаментозная терапия у пациентов с ишемической болезнью сердца в России и Европе: результаты российской части международного многоцентрового исследования EUROASPIRE IV. Кардиология 2016; 12: 5-11. |
| 799. | 19.25 | Погосова НВ, Оганов РГ, Бойцов СА, Аушева АК, Соколова ОЮ, Курсаков АА, Поздняков ЮМ, Гомыранова НВ, Карпова АВ, Алленов АМ. Эффективность контроля факторов риска у пациентов с высоким сердечно-сосудистым риском в России и других странах Европы. Сердце 2017 (в печати). |
| 800. | 19.26 | Yiannakopoulou ECh, Papadopulos JS, Cokkinos DV et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12(3): 243-249. |
| 801. | 19.27 | Taylor AA, Shoheiber O. Adherence to Antihypertensive TherapyWith Fixed-Dose Amlodipine Besylate/Benazepril HCl Versus Comparable Component-Based Therapy. Congestive Heart Failure 2003; 9(6): 324-32 |
| 802. | 19.28 | Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch |
| | | Intern Med 2006; 166(2): 155-60. |
| 803. | 19.29 | Webster R, Rodgers A. Polipill treatments for cardiovascular disease.Expert Opin Drug Deliv. 2016; 13(1): 1-6. doi: 10.1517/17425247.2016.1111869. Epub 2015 Nov 11. |
| 804. | 19.30 | Laufs U, Retting-Ewen V, Bohm M. Strategies to improve drug adherence. Eur Heart J 2011; 32: 264-268. |
| 805. | 19.31 | Марцевич СЮ, Навасардян АР, Кутишенко НП, Захарова АВ. Оценка приверженности к приему новых оральных антикоагулянтов у пациентов с фибрилляцией предсердий по данным регистра ПРОФИЛЬ. РФК 2014; 10(6): 625-30. |
| 806. | 19.32 | Колтунов И.Е., Погосова Г.В., Белова Ю.С. Эффективность различных программ вторичной профилактики у больных мягкой и умеренной артериальной гипертонией Кардиоваскулярная терапия и профилактика 2008; 7(6): 26-27. |
| 807. | 19.33 | Ghisi GL, Abdallah F, Grace SL, Thomas S, Oh P. A systematic review of patient education in cardiac patients: do they increase knowledge and promote health behavior change? Patient Educ Couns 2014; 95(2): 160-74. doi: 10.1016/j.pec.2014.01.012. Epub 2014 Jan 30. Review. |
| 808. | 19.34 | Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence inchronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 540–550. |
| | | 20. Профилактика ССЗ с помощью вакцинации |
| 809. | 20.1 | Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351: 2611–2618. |
| 810. | 20.2 | Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ 2010; 182: 1617–1623. |
| 811. | 20.3 | Gwini SM, Coupland CA, Siriwardena AN. The effect of influenza vaccination on risk of аcute myocardial infarction: self-controlled case- series study. Vaccine 2011; 29:1145–1149. |
| 812. | 20.4 | Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, Ciszewski A, Vakili H, Hoffman EB, Farkouh ME, Cannon CP. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013; 310: 1711– 1720. |
| 813. | 20.5 | Meschia JF, Bushnell B, Boden-Albala B et al. Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/ American Stroke Association. Stroke 2014; 45(12): 3754–832. |
| 814. | 20.6 | Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease: Executive Summary. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic |
| | | Surgeons. Circulation 2012; 126: 3097–3137. doi:10.1161/CIR.0b013e318277d6a0. |
| 815. | 20.7 | Davis ММ, Taubert К, Andrea L, Benin АL еt al. Influenza Vaccination as Secondary Prevention for Cardiovascular Disease. A Science Advisory from the AHA/ACC. Circulation 2006; 114: 1549-1553. |
| 816. | 20.8 | Диспансерное наблюдение больных c хроническими неинфекционными заболеваниями и с высоким риском их развития. Методические рекомендации. Под ред. Бойцова СА и Чучалина АГ. М.: 2014:112c . www.gnicpm.ru. |
| 817. | 20.9 | Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика 2011;10(6) Приложение 2. |
| 818. | 20.10 | Warren-Gash C, Hayward AC, Hemingway H, Denaxas S, Thomas SL, Timmis AD, Whitaker H, Smeeth L. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. J Infect Dis 2012; 206: 1652–1659. |
| 819. | 20.11 | de Diego C, Vila-Corcoles A, Ochoa O et al. Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. Eur Heart J 2008; 30: 209 – 216. |
| 820. | 20.12 | Бойцов СА, Лукьянов ММ, Платонова ЕВ и соавт. Исследование эффективности и безопасности вакцинопрофилактики гриппа у пациентов с болезнями системы кровообращения. Профилактическая медицина 2014; 6: 13 – 20. |
| 821. | 20.13 | Бойцов СА, Лукьянов ММ, Платонова ЕВ и соавт. Оценка эффективности вакцинопрофилактики гриппа у лиц, находящихся под диспансерным наблюдением по поводу болезней системы кровообращения. РФК 2016; 6: 703-710. |
| 822. | 20.14 | Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database of Systematic Reviews 2015, 5. No.: CD005050. DOI: 10.1002/14651858.CD005050.pub3. |
| 823. | 20.15 | Chang TY, Chao TF, Liu CJ, Chen SJ, Chung FP, Liao JN, Tuan TC, Chen TJ, Chen SA. The association between influenza infection, vaccination, and atrial fibrillation: A nationwide case-control study. Heart Rhythm 2016; 13(6): 1189 – 94. |
| 824. | 20.16 | Shay DK, Chillarige Y, Kelman J, Forshee RA, Foppa IM, Wernecke M, Lu Y, Ferdinands JM, Iyengar A, Fry AM, Worrall C, Izurieta HS. Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012– 2013 and 2013-2014. J Infect Dis 2017; 215(4): 510-517. |
| 825. | 20.17 | Ren S, Newby D, Li SC, Walkom E, Miller P, Hure A, Attia J. Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis. Open Heart 2015; 2(1): e000247. Published online 2015 Jun 26. doi: 10.1136/openhrt-2015-000247 |
| 826. | 20.18 | Vlachopoulos CV, Terentes-Printzios DG, Aznaouridis KA, Pietri PG, Stefanadis CI. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies. Eur J Prev Cardiol 2015; 22(9):1185-99. |
| 827. | 20.19 | Ren S, Hure A, Peel R, D'Este C, Abhayaratna W, Tonkin A, Hopper I, Thrift AG, Levi C, Sturm J, Durrheim D, Hung J, Briffa T, Chew DP, Anderson P, Moon L, McEvoy M, Hansbro P, Newby D, Attia J. AUSPICE study group. Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). Am Heart J 2016; 177: 58 – 65. |
| 828. | 20.20 | Министерство здравоохранения Российской Федерации. Инструкция по применению лекарственного препарата Пневмо 23 (Вакцина пневмококковая поливалентная полисахаридная) от 18.02.2014 № 011092 |
| 829. | 20.21 | Мареев ВЮ, Фомин ИВ, Агеев ФТ, Арутюнов ГП, Беграмбекова ЮЛ, Беленков ЮН, Васюк ЮА, Галявич АС, Гарганеева АА, Гендлин ГЕ, Гиляревский СР, Глезер МГ, Драпкина ОМ, Дупляков ДВ, Кобалава ЖД, Козиолова НА, Лопатин ЮМ, Мареев ЮВ, Моисеев ВС, Недошивин АО и соавт. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Журнал Сердечная Недостаточность 2017; 18 (1): 3-40 |
| | | 21. Профилактика ССЗ в условиях первичного звена |
| 830. | | Бойцов СА, Калинина АМ, Ипатов ПВ. Новые клинико- организационные подходы к профилактике сердечно-сосудистых заболеваний в системе первичной медико-санитарной помощи. Терапевтический архив 2013; 85(9): 4-10. |
| 831. | | Бойцов СА, Ипатов ПВ, Калинина АМ и соавт. Диспансеризация определенных групп взрослого населения. Методические рекомендации. Москваю 2015 (3-е издание с дополнениями иуточнениями) |
| 832. | | Калинина АМ, Гомова ТА, Кушунина ДВ и соавт. Профилактическая активность врачей-терапевтов амбулаторно-поликлинических учреждений как важный фактор эффективности диспансеризации и диспансерного наблюдения (региональный опыт). Профилактическая медицина 2016; 19(4): 15-22. |
| | | 22. Кардиореабилитация |
| 833. | 21.1 | Anderson L, Taylor RS. Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2014; 12: CD011273. |
| 834. | 21.2 | Anderson L, Oldridge N, Thompson DR, Zwisler A-D, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. J Am Coll Cardiol 2016; 67: 1–12. |
| 835. | 21.3 | Clark RA, Conway A, Poulsen V, Keech W, Tirimacco R, Tideman P. Alternative models of cardiac rehabilitation: a systematic review. Eur J Prev Cardiol 2015; 22: 35–74. |
| 836. | 21.4 | Karmali KN, Davies P, Taylor F, Beswick A, Martin N, Ebrahim S. Promoting patient uptake and adherence in cardiac rehabilitation. Cochrane Database Syst Rev 2014; 6: CD007131. |
| 837. | 21.5 | McAlister FA, Lawson FM, Teo KK, Armstrong PW. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ 2001; 323: 957–962. |
| 838. | 21.6 | Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlle trial in primary care. BMJ 2003; 326: 84. |
| 839. | 21.7 | Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, Holden A, De Bacquer D, Collier T, De Backer G, Faergeman O. Nurse-coordinated multidisciplinary, family based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008; 371: 1999-2012. |
| 840. | 21.9 | Allen JK, Dennison-Himmelfarb CR, Szanton SL, Bone L, Hill MN, Levine DM West M, Barlow A, Lewis-Boyer L, Donnelly-Strozzo M, Curtis C, Anderson K. Community Outreach and Cardiovascular Health (COACH) Trial: a randomized, controlled trial of nurse practitioner/community health worker cardiovascular disease risk reduction in urban community health centers. Circ Cardiovasc Qual Outcomes 2011; 4: 595–602. |
| 841. | 21.10 | Jorstad HT, von Birgelen C, Alings AM, Liem A, van Dantzig JM, JaarsmaW, Lok DJ, Kragten HJ, de Vries K, de Milliano PA, Withagen AJ, Scholte Op Reimer WJ, Tijssen JG, Peters RJ. Effect of a nurse-coordinated prevention programme oncardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial. Heart 2013; 99: 1421–1430. |
| 842. | 21.11 | Аронов ДМ, Бубнова, Иванова ГЕ. Организационные основы кардиологической реабилитации в России: современный этап. Cardioсоматика 2012; 4: 46-54. |
| 843. | 21.12 | Piepoli MF, Corra U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B, Cupples M, Dendale P, Doherty P, Gaita D, Hofer S, McGee H, Mendes M, Niebauer J, Pogosova N, Garcia-Porrero E, Rauch B, Schmid JP, Giannuzzi P. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol 2014; 21: 664–681. |
| 844. | 21.13 | Krumholz HM, Brindis RG, Brush JE, et al. Standards for statistical models used for public reporting of health outcomes:An American Heart Association Scientific Statement from the Quality of Care and Outcomes Research Interdisciplinary Writing Group: Cosponsored by the Council on Epidemiology and Prevention and the Stroke Council. Circulation 2006; 113: 456-462. |
| 845. | 21.14 | Oldridge N. Exercise-based cardiac rehabilitation in patients with coronary heart disease: meta-analysis outcomes revisited. Future Cardiol 2012; 8: 729–51. |
| 846. | 21.15 | Бубнова МГ, Аронов ДМ, Иванова ГЕ, Бойцов СА и соавт. Пилотный проект «Развитие системы реабилитации больных с сердечно- сосудистыми заболеваниями в лечебных учреждениях субъектов Российской Федерации». Результаты трехлетнего наблюдения. Вестник восстановительной медицины 2016; 4(74): 2-11 |
| 847. | 21.16 | Bjarnason-Wehrens B, McGee H, Zwisler AD, Piepoli MF, Benzer W, |
| | | Schmid JP, Dendale P, Pogosova NG, Zdrenghea D, Niebauer J, Mendes M. Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation Inventory Survey. Eur J Cardiovasc Prev Rehabil 2010; 17:410–418. |
| 848. | 21.17 | Погосова НВ, Оганов РГ, Бойцов СА, Аушева АК, Соколова ОЮ, Курсаков АА, Поздняков ЮМ, Салбиева АО, Лельчук ИН, Гусарова ТА, Гомыранова НВ, Сказин НА, Елисеева НА, Ахмедова ЭБ, Бедейникова КК, Ковригина МН. Мониторинг вторичной профилактики ишемической болезни в России и Европе: результаты российской части международного многоцентрового исследования EUROASPIRE IV. Кардиология, 2015; 55 (12): 99-107. |
| 849. | 21.18 | Grace SL, Turk-Adawi KI, Contractor A, Atrey A, Campbell N, Derman W, Melo Ghisi GL, Oldridge N, Sarkar BK, Yeo TJ, Lopez-Jimenez F, Mendis S, Oh P, Hu D, Sarrafzadegan N. Cardiac rehabilitation delivery model for low-resource settings. Heart 2016 Sep 15; 102(18): 1449–1455. |
| 850. | 21.19 | Sanderson BK, Southard D, Oldridge N; Writing Group. AACVPR consensus statement. Outcomes evaluation in cardiac rehabilitation/secondary prevention programs: improving patient care and program effectiveness. J Cardiopulm Rehabil. 2004; 24(2): 68-79. |
| 851. | 21.20 | Kotseva K, Wood D, De Backer G, De Bacquer D. Use and effects of cardiac rehabilitation in patients with coronary heart disease: results from the EUROASPIRE III survey. Eur J Prev Cardiol 2013; 20: 817-–826. |
| 852. | 21.21 | Аронов ДМ, Бубнова МГ, Иоселиани ДГ, Красницкий ВБ, Шовкун ТВ, Новикова НК, Ярных ЕВ. Комплексная программа реабилитации больных ишемической болезнью сердца после коронарного шунтирования в условиях поликлинического кардиореабилитационного отделения: клинические эффекты третьего этапа реабилитациию. Кардиология 2017; 3: 10-19. |
| 853. | 21.22 | Gravely-Witte S, Leung YW, Nariani R, Tamim H, Oh P, Chan VM, Grace SL. Effects of cardiac rehabilitation referral strategies on referral and enrollment rates. Nat Rev Cardiol 2010; 7: 87–96. |
| 854. | 21.23 | Jolly K, Taylor RS, Lip GYH, Stevens A. Home-based cardiac rehabilitation compared with centre-based rehabilitation and usual care: a systematic review and meta-analysis. Int J Cardiol 2006; 111(3): 343–351. |
| 855. | 21.24 | Taylor R, Dalal H, Jolly K, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev 2010; 1: CD007130. |
| 856. | 21.25 | Dalal HM, Zawada A, Jolly K, et al. Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. BMJ 2010; 340: b5631. |
| 857. | 21.26 | Clark AM, Haykowsky M, Kryworuchko J, et al. A meta-analysis of randomized control trials of home-based secondary prevention programs for coronary artery disease. Eur J CardiovascPrevRehabil 2010; 17(3): 261- 270. |
| 858. | 21.27 | Piotrowicz E, Korzeniowska-Kubacka I, Chrapowicka A, Wolszakiewicz J, Dobraszkiewicz-Wasilewska B, Batogowski M, PiotrowskiW, Piotrowicz R. Feasibility of home-based cardiac telerehabilitation: results of TeleInterMed study. Cardiol J 2014; 21: 539–546. |
| 859. | 21.28 | Neubeck L, Redfern J, Fernandez R, Briffa T, Bauman A, Freedman SB. |
| | | Telehealth interventions for the secondary prevention of coronary heart disease: a systematic review. Eur J Cardiovasc Prev Rehabil 2009; 16: 281- 289. |
| 860. | 21.29 | Varnfield M, Karunanithi M, Lee CK, Honeyman E, Arnold D, Ding H, Smith C, Walters DL. Smartphone-based home care model improved use of cardiac rehabilitation in postmyocardial infarction patients: results from a randomised controlled trial. Heart 2014; 100: 1770-1779. |
| 861. | 21.30 | Giannuzzi P, Temporelli PL, Marchioli R, Maggioni AP, Balestroni G, Ceci V, Chieffo C, Gattone M, Griffo R, Schweiger C, Tavazzi L, Urbinati S, Valagussa F, Vanuzzo D. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Intern Med 2008; 168: 2194-2204. |
| | | 23. Стратегия вмешательства на популяционном уровне |
| 862. | 23.1 | Бойцов СА, Потемкина РА. Профилактика неинфекционных заболеваний и формирование здорового образа жизни: региональные межведомственные целевые программы как ключевое решение. Национальные проекты 2013; 1: 31 |
| 863. | 23.2 | Бойцов СА, Вылегжанин СВ, Гилева ФА и соавт. Совершенствование профилактики хронических неинфекционных заболеваний в учреждениях здравоохранения. Профилактическая медицина 2013; 16(2): 3-12 |
| 864. | 23.3 | Погосова НВ, Вергазова ЭК, Аушева АК, Юсубова АИ, Исакова СС, Бойцов СА. Актуальные результаты работы центров здоровья России. Профилактическая медицина 2016: 6; 50-58. doi: 10.17116/profmed201619550-58. |
| 865. | 23.4 | Проект Стратегии формирования здорового образа жизни населения, профилактики и контроля неинфекционных заболеваний на период до 2025 года. Дата публикации 26.06.2017 г. https://www.gnicpm.ru/UserFiles/Strategy_draft_26062017.pdf. |
| 866. | 23.5 | Jorgensen T, Capewell S, Prescott E, Allender S, Sans S, Zdrojewski T, De Bacquer D, de Sutter J, Franco OH, Logstrup S, Volpe M, Malyutina S,Marques-Vidal P, Reiner Z, Tell GS, Verschuren WM, Vanuzzo D. Populationlevelchanges to promote cardiovascular health. Eur J Prev Cardiol 2013; 20: 409–421. |
| 867. | 23.6 | EU platform on diet, physical activity and health. European Union 2005. http://ec.europa.eu/health/archive/ph_determinants/life_style/nutrition/ platform/docs/platform_charter.pdf |
| 868. | 23.7 | European Heart Network. Diet, Physical Activity and Cardiovascular Disease Prevention in Europe. Brussels, Belguim: European Heart Network 2011. |
| 869. | 23.8 | Global Advocacy Council for Physical Activity, International Society for Physical Activity and Health. The Toronto Charter for Physical Activity: a global call for action. J Physical Activity Health 2010; 7( 3): 370–385. |
| 870. | 23.9 | Kriemler S, Zahner L, Schindler C, Meyer U, Hartmann T, Hebestreit H, Brunner La Rocca HP, van Mechelen W, Puder JJ. Effect of school based physical activity programme (KISS) on fitness and adiposity in primary schoolchildren: cluster randomised controlled trial. BMJ 2010; 340: 785. |
| 871. | 23.10 | Kerr J, Eves F, Carroll D. Six-month observational study of prompted stair climbing. Prev Med 2001; 33: 422-427. |
| 872. | 23.11 | Mozaffarian D, Afshin A, Benowitz NL, Bittner V, Daniels SR, Franch HA, Jacobs DR Jr, Kraus WE, Kris-Etherton PM, Krummel DA, Popkin BM, Whitsel LP, Zakai NA. Population approaches to improve diet, physical activity, and smoking habits: a scientific statement from the American Heart Association.Circulation 2012; 126: 1514-1563. |
| 873. | 23.12 | World Health Organization. Guidelines for implementation. WHO Framework Convention on Tobacco Control. Articles 5.3: 8-14. Geneva:World Health Organization 2011. |
| 874. | 23.13 | World Health Organization. Global status report on alcohol and health. http://apps. who.int/iris/bitstream/10665/112736/1/9789240692763_eng.pdf. |
| 875. | 23.14 | Klatsky AL. Alcohol and cardiovascular mortality: common sense and scientific truth. J Am Coll Cardiol 2010; 55: 1336-1338. |
| 876. | 23.15 | Britton A, McKee M. The relation between alcohol and cardiovascular disease in Eastern Europe: explaining the paradox. J Epidemiol Community Health 2000; 54: 328-332. |
| 877. | 23.16 | Anderson P. Global alcohol policy and the alcohol industry. Curr Opin Psychiatry 2009; 22: 253-257. |
| 878. | 23.17 | Wagenaar AC, Salois MJ, Komro KA. Effects of beverage alcohol price and tax levels on drinking: a meta-analysis of 1003 estimates from 112 studies. Addiction 2009; 104: 179-190. |
| 879. | 23.18 | Her M, Giesbrecht N, Room R, Rehm J. Privatizing alcohol sales and alcohol consumption: evidence and implications. Addiction 1999; 94: 1125-1139. |
| 880. | 23.19 | Newby DE, Mannucci PM, Tell GS, Baccarelli AA, Brook RD, Donaldson K,Forastiere F, Franchini M, Franco OH, Graham I, Hoek G, Hoffmann B, Hoylaerts MF, Kunzli N, Mills N, Pekkanen J, Peters A, Piepoli MF, Rajagopalan S, Storey RF. Expert position paper on air pollution and cardiovascular disease. Eur Heart J 2015; 36: 83-93. |